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Abstract 
 
 
Background and rationale 
Acute intracerebral haemorrhage (ICH) results from rupture of cerebral vasculature leading to 
bleeding into the cerebral parenchyma. ICH represents 10-50% of stroke, depending on the 
population studied, is associated with significant morbidity and mortality, and has limited 
treatment options.  The INTERACT2 trial was designed to assess the role of blood pressure 
lowering therapy in intracerebral haemorrhage. Guideline therapy (target systolic blood pressure 
[SBP] <180 mmHg) was compared against intensive lowering (SBP <140 mmHg). The 
outcomes assessed in this trial were death or major disability (according to the modified Rankin 
scale at 90 days) following ICH. Hyperglycaemia has been widely studied in acute illnesses as 
myocardial infarction, ischaemic stroke, traumatic brain injury and ICH, and is associated with 
adverse outcomes. The incidence of hyperglycaemia in the acute phase is due to a combination 
of factors: diabetic pathophysiology and stress hyperglycaemia. Animal models have specifically 
examined hyperglycaemia in ICH and have found association with haematoma volume, 
expansion and perihaematomal oedema. Accordingly, I performed secondary analyses in the 
INTERACT2 dataset to determine the association between hyperglycaemia and outcomes. The 
aim was also to understand the underlying mechanism and assess the potential role of 
hyperglycaemic management in ICH.  
 
Methods 
The INTERACT2 cohort was divided into two groups: normoglycaemia (blood glucose level 
<6.5) and hyperglycaemia (blood glucose level >6.5). Baseline characteristics were summarised 
as mean (standard deviation [SD]) or median (interquartile range [IQR]) for continuous 
variables, and as number (%) for categorical variables. Collinearity and interactions between 
variables were checked.  Independent associations between baseline characteristics and level of 
blood glucose (normoglycaemia and hyperglycaemia) and history of diabetes mellitus, were 
examined in multivariable logistic regression models. Adjustment was made for all significant 
baseline variables to determine independent predictors of hyperglycaemia. 90-day clinical 
outcomes studied were: death alone, major disability lone and death or major disability. 
Abstract 
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Multivariable logistic regression models adjusted by all the significant and clinically important 
baseline variables as well as significant interactions were used to determine associations of 
baseline level of blood glucose, both as continuous and categorical (fourths) variables, and 
clinical outcomes, as well as the association between a history of diabetes mellitus and clinical 
outcomes. Blood glucose data was also categorised based on diagnostics thresholds (<6.1, 6.1–
7.0, >7.0 mmol/L) and sensitivity analyses were performed to further examine associations with 
primary outcomes. Univariate analysis was also performed to determine associations with 24 
hour neurological deterioration, non-fatal adverse events and causes of death. The associations of 
hyperglycaemia on absolute increase in haematoma and perihaematomal oedema volumes over 
24 hours were assessed by an analysis of covariance (ANCOVA) including the same adjusted 
variables above.   
 
Results 
Of the 2829 ICH patients, 176 were excluded because of missing baseline blood glucose 
measurements. Of the remaining 2653 patients, 1348 (51%) presented with hyperglycaemia 
(>6.5 mmol/L) and 292 (11%) had a history of diabetes mellitus. Baseline characteristics of 
INTERACT2 patients were compared between normoglycaemic and hyperglycaemic patients. 
All characteristics with significant difference on univariate analysis were included in the 
multivariate model. On multivariate analyses, the independent predictors of hyperglycaemia at 
admission were: female gender, patients outside of China, stroke severity (by National Institutes 
of Health stroke scale (NIHSS) score), systolic blood pressure (SBP), history of diabetes, cortical 
location of the haematoma, intraventricular haemorrhage (IVH) extension, and haematoma 
volume (ICH only). In non-diabetic patients, independent predictors were female sex, 
recruitment outside of China, high NIHSS score (an indicator of more severe neurological 
impairment), cortical location of ICH, large volume haematoma, and IVH extension. Primary 
and secondary outcomes were compared by admission blood glucose. There was a strong and 
near continuous relationship between baseline blood glucose level and death or major disability 
(odds ratio [OR] 1.29, 95% confidence interval [CI] 1.19-1.40; P<0.0001) and death (OR 1.23, 
95%CI 1.12-1.37; P<0.0001) at 90 days, and these variables remained significant when adjusted 
for other confounders and significant interactions: adjusted odds ratio [aOR] 1.11, 95%CI 1.00-
1.24; P<0.0001, aOR 1.16 95% CI (1.01-1.33); P=0.043 for death or major disability and death, 
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respectively. Quartile analysis of admission blood glucose showed significant association with 
poorer outcomes in the highest quartile (aOR 1.35, 95%CI 1.01-1.80, P=0.015). For secondary 
outcomes: early neurological deterioration, non-fatal serious adverse events and fatal serious 
adverse events were all significantly greater in hyperglycaemic patients. Hyperglycaemic 
patients had significantly higher baseline haematoma volumes, with (14.6 vs 11.6 mL, P 
<0.0001) and without intraventricular haemorrhage (11.6 vs 10.2 ml, P <0.01), and less deep 
(78.8% vs. 86.5%, P <0.001) and more cerebellar (5.9% vs. 1.1%, P <0.01) haematomas. 
Diabetic patients had significantly lower haematoma volume in comparison with non-diabetics 
(DM 9.2 mL vs. NDM 11.2 mL; p < 0.01) whilst there was no association with haematoma 
location or IVH extension.  Hyperglycaemic patients had no difference in haematoma growth 
(mean adjusted, 5.1% vs 6.8%, P =0.13) and perihaematomal oedema (mean adjusted 86.0% vs 
94.1%, P =0.46) in the first 24 hours.  
 
Discussion and conclusions 
Admission hyperglycaemia and history of diabetes mellitus was shown to be an independent 
predictor of poor outcome in patients with predominantly mild to moderate severity of ICH 
(INTERACT2 cohort). Significantly greater adverse events (fatal and non-fatal) and early 
neurological deterioration was also found in the hyperglycaemic patients. The underlying 
mechanism of the hyperglycaemia may be a combination of diabetic pathophysiology and the 
physiological stress response. This was reflected in the determinants of hyperglycaemia which 
included history of diabetes mellitus, haematoma characteristics (ICH volume, superficial 
haematoma location, IVH extension), ICH severity by NIHSS score and demographic factors 
(females, recruitment outside China). Interestingly, diabetic patients presented with significantly 
lower haematoma volumes and no association with haematoma location or IVH extension, 
suggesting distinct pathophysiology between diabetic hyperglycaemic and non-diabetic 
hyperglycaemic patients. 
 
Whilst animal models suggest that hyperglycaemia exacerbates haematoma expansion and 
perihaematomal oedema, these associations were not observed in INTERACT2 analyses. 
However, hyperglycaemic patients did present with significantly greater IVH extension, baseline 
haematoma volumes, and of cerebellar and cortical location of the haematomas. More detailed 
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haematoma location analysis is required to determine if specific cerebral regions responsible for 
glucose homeostasis are affected in hyperglycaemic patients as this will reveal more about the 
underlying cause for hyperglycaemia. Significantly higher baseline SBP was found in 
hyperglycaemic patients and further analyses is required to identify the benefit of intensive blood 
pressure lowering in patients presenting with admission hyperglycaemia.  
 
There are limited data and guidelines regarding the management of hyperglycaemia in ICH. 
Intensive insulin therapy creates the risk of hypoglycaemic events which threatens to worsen 
outcome. However, the results of this investigation illustrate significant association between 
hyperglycaemia and adverse outcomes. Based on these findings, there is justification in 
proceeding with a clinical trial to evaluate benefits and harms of therapy to control 
hyperglycaemia in ICH.  
  
Acknowledgements 
 
Page 13 of 94 
 
Acknowledgements 
 
 
First and foremost I would like to thank my primary supervisor, Professor Craig Anderson, at 
The George Institute for Global Health. I met him during my first year of medical school when I 
embarked on this Master’s degree and throughout this journey he has been a constant support. He 
has provided guidance, direction and motivation at every step. He has always encouraged me in 
my endeavours and supported my decisions over the course of this degree.  
 
I would also like to sincerely thank my co-supervisors, Professor Hisatomi Arima and Dr Emma 
Heeley, who assisted me in the early stages of my research in formulating my research questions. 
Since then they have provided critiques and comments on all my work which has allowed me to 
complete this thesis.  
 
I must also thank Dr Xia Wang who has been an immense support throughout this thesis. She has 
been integral in assisting with my statistical analyses. She has always been patient and available 
to answer my questions whilst also providing comments on how I can improve my work.  
  
Chapter 1: Introduction 
 
Page 14 of 94 
 
Chapter 1: Introduction 
 
Intracerebral Haemorrhage: Burden and Aetiology 
Burden of Stroke  
Stroke is the second highest cause of death and the leading cause of disability and costing $2.14 
billion to Australians annually. Each year there are predicted to be 60000 new and recurrent 
strokes. Intracerebral haemorrhage (ICH) is characterised by bleeding within the parenchyma of 
the brain and accounts for 10-50% of strokes and is associated with significant mortality. 
Globally, from 1990 to 2010, the incidence of ICH decreased in high-income countries (12%, 
95% CI 6-17), whilst increased (12%, 95% CI -3 to 22) in low and middle-income countries who 
have a significant burden of stroke through high incidence, prevalence, mortality, disability-
adjusted life years (DALYs) lost
1
.  Specifically, examining stroke in high-income countries from 
2000-2008, the mortality following ICH was 41.0% in comparison with ischaemic stroke 
(14.3%) and subarachnoid haemorrhage (SAH) (30.0%).  In contrast, stroke mortality for low 
income countries for ICH, SAH and ischaemic stroke, was 38.7%, 43.9% and 16.7%, 
respectively.  
A systematic review and meta-analyses by Van Asch et al.
2
 assessed 36 eligible studies of the 
incidence, mortality and functional outcome for ICH during 1980-2008.  1-month mortality of 
40.4% was reported, however, few data pertained to outcomes beyond 3-months. Functional 
outcomes were available for 6 of the 36 included trials, thereby requiring further data.  
The specific costs of stroke subsets in the Australian population were investigated in NEMESIS 
study
3
 and found that ICH accounted for 26% of stroke costs ($334.5 million) compared to 
$936.8 million (72%) attributed to ischaemic stroke. Anterior circulation ischaemic stroke were 
responsible for the greatest hospitalisation costs followed by ICH, however, average lifetime 
costs were greater in ICH and were 1.6-2 fold greater than ischaemic stroke. Similar findings 
were presented in a German population study
4
 where the economic burden and management 
strategies were followed for one year post-ICH. Compared with ischaemic stroke, ICH had 
greater hospital and rehabilitation costs, hospitalisation periods and admission rates to intensive 
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care units (ICU). Gender differences have also been reported in the literature, with females 
associated with poorer outcomes and greater mortality
5,6
 in studies with multivariate modelling. 
Functional outcomes were also assessed and revealed reduced problem solving ability (47.9%), 
memory storage and retrieval capacity (50.9%), vision impairment (29.4%) and decreased speech 
comprehension (29.2%)
4
. Another investigation showed a potential association with dementia 
and cognitive impairment following ICH
7
 with domains of executive function, episodic memory 
and psychomotor speed being affected. The wide range of neuropsychological and cognitive 
impairments associated post-ICH may contribute to the significant societal and individual burden 
of this disease process.  
Causes of Intracerebral Haemorrhage 
ICH refers to the extravasation of blood outside the cerebral vasculature into brain parenchyma. 
A number of risk factors and causes for ICH have been identified. The most important is 
hypertension.  Others relate to various vasculopathies, abnormal coagulation, specific genetic 
markers, cerebral aneurysms, and arteriovenous malformations (AVMs). Use of specific 
medications, in particular anticoagulants and antiplatelet agents, also cause ICH, whilst the role 
of common chronic diseases such as diabetes mellitus has also been proposed yet remains 
debated. Age remains the most significant non-modifiable risk factor.  
Hypertension 
Hypertension has been established as a significant aetiological factor associated with ICH with a 
number of proposed mechanisms, such as oxidative stress that disrupts the cerebral circulation. 
Activation of the renin-angiotensin system (RAS) in hypertension leads to increased superoxide 
production. Animal models have shown that elevated superoxide levels were associated with 
greater incidence and volumes of ICH
8
. Didion et al.
9
 explored the role of copper zinc 
superoxide dismutase in protecting against endothelial dysfunction and superoxide induced 
damage, whilst also reporting a concentration dependent effect of angiotensin II in causing 
increased superoxide levels. However, experimental models testing clinical relevance of 
oxidative stress in ICH found injections of superoxide dismutase yielded no reduction in 
neurological injury
10
.  
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Another proposed mechanism links the pathology of hypertensive ICH through the reactive 
hyperplasia within the vascular smooth muscle leading to collagen type IV deposits in the 
endothelial wall
11
. This fibrinoid necrosis within the vasculature may alter its contractility and 
distribution of these pathological vessels in high-pressure regions (diencephalon, basal ganglia) 
may represent the association with ICH
12
.  
Vasculopathy  
Cerebral amyloid angiopathy (CAA) is a vasculopathy where amyloid (Aβ) protein accumulates 
within the endothelium of cerebral vasculature specifically in cortical vessels. These proteins 
aggregate within the tunica media and adventitia and disease progression results in degeneration 
of the vessel wall. β-amyloid deposition activates matrix metalloproteinases which may further 
contribute to the deterioration of cerebral vasculature.
13
 This fragility in cerebral blood vessels 
leads to microaneurysm formation and is reported to be responsible for 12-15% of lobar located 
ICH. Early investigations reported this vasculopathy induced ICH,
14
 whilst Wagle et al.
15
 
through a radiographic case series, underlined CAA as a cause of ICH. More recently differences 
between CAA and hypertensive pathology were investigated.
16
 With differing patterns of 
involved vasculature, the surgical management is also distinct in CAA-induced ICH.  
Genetic causes of ICH and CAA 
Genetic factors related to both hypertension and CAA may also contribute to the aetiology of 
ICH. The apolipoprotein gene APOE-ε4 has an established role in the pathology of Alzheimer’s 
disease
17,18
, however, a strong positive correlation has also been reported with CAA.
19
  
The role of apolipoprotein E is to maintain cerebrovascular function, however, the APOE4 
isoform results in blood-brain barrier disruption, susceptibility to uptake of neurotoxic proteins 
and overall neurodegeneration. Greenberg et al.
20
 found that the ApoE-ε4 genotype has an 
independent effect, distinct from Alzheimer’s disease, upon CAA as well CAA-associated ICH. 
This gene was further linked with 5 years earlier onset of lobar ICH in comparison with controls. 
The genetic correlation with CAA-induced lobar ICH has been extensively investigated and it 
has been proposed that ApoE-ε2 increases the incidence of vascular rupture and this effect is 
independent of Alzheimer’s pathology. In contrast, ApoE-ε4 is associated with greater amyloid 
deposition in the vessel wall, atherosclerotic changes and is correlated with Alzheimer’s 
Disease.
21
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The ApoE ε4 was also found to be independently associated with lobar ICH.22 A Chinese 
population study of ICH patients found higher frequency of patients with ε3/ε4 allele compared 
to controls,
23
 whilst the presence of either ε2 or ε4 resulted in a 28% recurrence rate in 
comparison to 10% for normal controls
24
. In addition, recent investigation
25
 demonstrated that 
the ε2 genotype was also associated with haematoma expansion as observed in patients with 
lobar ICH. This expansion was even greater in patients with CAA indicating there may be a 
common mechanism between these aetiological factors.  
Vascular changes and defects 
The formation of aneurysms and presence of AVM are also considered significant risk factors for 
ICH. Although aneurysmal rupture is most commonly associated with subarachnoid 
haemorrhage, ICH from intracavernous carotid artery
26
 and anterior ethmoidal artery
27
 
aneurysms have been reported. AVM are embryonic vascular malformations caused by direct 
anastomoses between cerebral arterial and venous vasculature. AVM increase the risk of ICH, 
are associated with poorer outcomes and there is a greater incidence of rupture post-ICH
28
.  
Haematological and coagulation disorders 
Haematological disorders such as haemophilia, vitamin K deficiency, coagulation defects and 
von Wildebrand factor deficiency, increase bleeding risk and are therefore linked with more 
severe ICH. For both Haemophilia A and B spontaneous ICH is frequently reported with the 
neonatal risk being 40-80 times greater than the normal population
29
. Vitamin K deficiency in 
ICH was investigated in the Turkish population and reported 33% case mortality.
30
 Specifically, 
coagulopathies have been linked with lobar ICH
31
 and short-term mortality (1-month) was found 
to be significantly higher in patients with elevated bleeding profiles (International Normalised 
Ratio, INR). Liver dysfunction is another proposed aetiological factor of ICH possibly through 
effects upon platelet function and coagulation. Fujii et al.
32
 examined this association and found 
significantly greater mortality and haematoma volumes in patients with liver dysfunction.  
Diabetes mellitus 
Diabetes mellitus is a metabolic disease with multi-system complications. It is a known risk 
factor for coronary artery disease, myocardial infarction, and ischaemic stroke, and is associated 
with poor outcome. However, the association with ICH is not robust. Epidemiological analyses 
reveal the relative risk of ICH in diabetics as 1.6 in comparison with non-diabetics
33
, however, 
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population studies in Iran contrast these findings and show no association between ICH and 
diabetes mellitus.
34
   
The association of diabetes mellitus with adverse outcomes following ICH has also been 
investigated with conflicting results. Earlier studies found significantly higher mortality rates in 
diabetics (54.5%) in comparison with non-diabetics (26.3%),
35
 and at 7 and 30-days
36
. In 
contrast, prospective analysis of 1438 Chinese patients found no association with adverse 
outcomes.
37
 Therefore, conflicting evidence exists regarding this association with further 
analysis required for a more comprehensive understanding.  
Potential mechanisms underlying diabetes-induced ICH involve diabetic ketoacidosis (DKA) and 
microvascular complications. The diabetic hyperglycaemic state increases oxidative stress 
thereby disrupting endothelial cells and damaging microvasculature. Associated systemic 
inflammation also contributes to various signalling pathways which disrupt endothelial function 
and exacerbate neurological injury.
38
 Another mechanism by which diabetes may predispose 
individuals to ICH is through the formation of atherosclerotic plaques in the vascular 
endothelium. The hyperglycaemic state results in non-enzymatic glycosylation of lipids and 
proteins, thereby accelerating atheroma formation.
39
 With existing uncertainty in the role of 
diabetes mellitus in ICH, further investigation is required to explore this association and 
understand potential mechanisms involved.  
This thesis examines the incidence of stress hyperglycaemia and its independent predictors in 
ICH patients (Chapter 2). It analyses outcomes of early neurological deterioration and longer 
term outcomes of 3-month major disability and death (Chapter 3). Comparisons of haematoma 
volumes, intraventricular extension and haematoma location are also explored in patients with 
normal and elevated admission blood glucose levels (Chapter 4). We hypothesised that patients 
with admission hyperglycaemia would have significantly higher incidence of early neurological 
deterioration and poorer longer term outcomes (death or major disability) at 3 months. Other 
hypotheses were that patients with admission hyperglycaemia would have more severe 
haematoma characteristics such as larger haematoma volume, higher rates of intraventricular 
extension, haematoma growth and perihaematomal oedema.  
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Chapter 2 - Stress hyperglycaemia and its 
determinants 
 
 
2.1 Presentation Details 
Oral Presentation at Stroke Society of Australasia (SSA) annual scientific meeting in 2016 
(Brisbane) 
2.2 Abstract 
Determinants of hyperglycaemic response in intracerebral haemorrhage: INTERACT2 
results  
A Saxena,
1,2
 CS Anderson,
1,2,3
 X Wang,
1,2
 E Chan,
1,2 
H Arima,
1,2
 E Heeley,
1
 C Delcourt,
1,2,3
 C 
Stapf,
4
 M Parsons,
5
 P Lavados,
6
 T Robinson,
7
 Y Huang,
8
 for the INTERACT Investigators 
1
The George Institute for Global Health, 
2
Central Clinical School, University of Sydney 
3
Neurology Department, Royal Prince Alfred Hospital, Sydney, NSW, Australia  
4
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), 
Département de Neurosciences, Université de Montréal, Montréal, QC, Canada  
5
Department of Neurology, John Hunter Hospital, University of Newcastle, Newcastle, New 
South Wales, Australia; 
6
Servicio de Neurología, Departamento de Medicina. Clínica Alemana, Universidad del 
Desarrollo, Santiago, Chile;  
7
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Background and Purpose:  Hyperglycaemia is common after acute intracerebral haemorrhage 
(ICH) and is associated with adverse outcomes.  We aimed to identify the determinants of 
hyperglycaemic response among participants of the INTERACT2 study.  
Methods:  INTERACT2 was an international, multicentre, prospective, open, blinded endpoint, 
randomised controlled trial of 2839 ICH patients (<6hr) with elevated systolic blood pressure 
(SBP) assigned to intensive (target SBP <140mmHg) or guideline-based (SBP <180mmHg) BP 
management.  Determinants of baseline hyperglycaemia were identified in multivariable logistic 
regression models.  
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Results:  Available baseline data on blood glucose in 2653 (93%) patients showed. significant 
predictors of hyperglycaemia were female sex, recruitment outside China, high SBP, high 
NIHSS score, history of diabetes mellitus, cortical location of ICH, large haematoma volume, 
and intraventricular extension (all P<0.001).  Independent predictors of hyperglycaemia in non-
diabetic patients (n = 2361) were female sex, high SBP, recruitment outside of China, high 
NIHSS score, cortical location of ICH, large volume haematoma and intraventricular extension.  
Conclusions:  Hyperglycaemic reaction in acute ICH reflects a combination of physiological 
stress related to the severity of underlying disease and associated dysglycaemia from associated 
diabetes mellitus.  
2.3 Hyperglycaemia in acute medical conditions and association with adverse 
outcomes 
Hyperglycaemia refers to the elevation in plasma glucose and is a clinical finding that is linked 
with many emergency scenarios such as ICH, acute myocardial infarction (AMI), trauma and 
ischaemic stroke. The incidence of hyperglycaemia has further been found to be specifically 
associated with adverse functional outcomes and increased rates of mortality. Increased hospital 
mortality has been reported with increments in blood glucose and adverse outcomes seen with 
admission hyperglycaemia.
40
 This raises the question of the mechanism and whether the stress 
hyperglycaemia or an underlying diabetic pathophysiology needs to be considered.  
 
Admission hyperglycaemia has also been linked with adverse outcomes in other neurological 
disease processes such as traumatic brain injury where there is an association with infectious 
morbidity
41
, severe disability and mortality
42
 and acute ischaemic stroke where admission 
hyperglycaemia is correlated with haemorrhagic transformation
43
 and adverse outcomes at 3-
months
44
.  
The presentation of hyperglycaemia has been considered independent of diabetes as non-diabetic 
patients presenting to cardiac and neurosurgical units reported significantly increased mortality.
45
 
In critical illness, hyperglycaemia has been observed in 38% of patients, of which a significant 
proportion are non-diabetic. Non-diabetic hyperglycaemic patients are at greater risk of adverse 
outcomes with 16% mortality in comparison with 3% mortality reported in diabetic 
hyperglycaemic patients.
46
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In terms of functional outcomes hyperglycaemic patients also had longer hospital admission 
periods and were more frequently admitted into rehabilitation or extended care facilities. The 
adverse outcomes linked with hyperglycaemia may be related to the increased risk of infectious 
complications in critical illness
47,48
 or the oxidative stress due to generation of oxygen free 
radicals.
49
  
Acute myocardial infarction and cardiac surgery 
Acute myocardial infarction generates a physiological stress and the resulting hyperglycaemia 
has been widely reported. Significantly higher in-hospital mortality has been reported in 
myocardial infarction patients presenting with hyperglycaemia (16%) in comparison with 
normoglycaemia (6%).
50
 However, when dividing the hyperglycaemic group into diabetics and 
non-diabetics there was no significant difference in mortality. These findings were affirmed by 
Capes et al.
51
 who demonstrated a 3.9 times greater risk of mortality in non-diabetic 
hyperglycaemic patients in comparison with normoglycaemic controls. This suggests that the 
association between hyperglycaemia and poorer outcomes is separate from diabetic 
pathophysiology. In myocardial infarction, potential pathways in the acute setting include 
activation of inflammatory cascades with increased levels of circulating interleukins, activation 
of T-cell differentiation and elevated inflammatory markers (C-reactive protein.
52
  
 
The hyperglycaemia may also exacerbate the myocardial necrosis due to oxidative stress and the 
p66Shc protein plays an integral role in regulating the oxidative equilibrium and causing cardiac 
mitochondrial dysfunction.
49
 This protein contributes to the production of hydrogen peroxide 
thereby stimulating mitochondrial apoptosis.
53
 The elevated blood glucose was also correlated to 
increased levels of myocardial necrotic factors such as Troponin I and creatine kinase MB.
54
 
This suggests that the hyperglycaemia is related to the physiological stress following infarction.  
 Adverse outcome have been reported following cardiac surgery and infectious complications 
(sternal wound infections) and longer hospitalisation is reported.
55
 These markers of poor 
outcome must also be assessed in ICH.  
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Direct clinical application may suggest that tighter glycaemic control would be advantageous, 
however, intensive insulin regimens have failed to show significant clinical benefit and resulting 
hypoglycaemic events must be weighed against the theoretical benefit.
56-58
 
Neurological conditions 
Hyperglycaemia has also been recorded in brain-related emergencies such as traumatic brain 
injury (TBI), acute ischaemic stroke and, most relevantly, ICH and these are linked with adverse 
outcomes based on morbidity and mortality.
59
 Jeremitsky et al.
60
 monitored blood glucose over 5 
days in TBI patients and found that early hyperglycaemia was linked with poorer functional 
outcomes (GCS) and mortality. Independent risk factors for patients requiring neurosurgical 
intervention (craniotomy) for management of TBI were hyperglycaemia, age, GCS <9 and 
severity of TBI.
61
 In this study the hyperglycaemic group had higher in-hospital mortality in 
comparison with normoglycaemic controls (31% vs 20%, p < 0.02). Paediatric TBI is another 
critical condition where the incidence of hyperglycaemia is associated with poor outcomes.
62,63
  
Ischaemic stroke 
In the context of ischaemic stroke, hyperglycaemia is observed in 20-50% of patients.
64
 
Specifically, higher mortality rates were reported at 30 days, 1 year and 6 years (p <0.01 for 
all).
65
 These findings have been confirmed in subsequent investigations reporting worsened 
clinical outcomes
66
 and significantly increased 28-day mortality
67
. An earlier study found no 
significant difference in survival or functional outcome between hyperglycaemia and 
normoglycaemic patients at 3 months
68
, however, this had a smaller cohort encompassing all 
stroke subtypes (lacunar infarcts, cerebral infarcts and ICH). 
ICH 
A number of investigations have demonstrated the presence of hyperglycaemia in ICH.
69-71
 
Stress hyperglycaemia was reported in 27.3% (n=109) of patients with 45% mortality in the 
hyperglycaemic group in comparison with 5% mortality in normoglycaemic patients.
71
 Other 
investigations found hyperglycaemia in 59.3% of patients at admission, with less than half of 
these (44%) experiencing prolonged hyperglycaemia at 72-hours. The association of 
hyperglycaemia and survival also shows significantly greater in-hospital and 3-month 
mortality.
72
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Numerous mechanisms involving oxidative stress, haematoma expansion and cerebral oedema 
have been discussed with respect to hyperglycaemia and ICH. Hyperglycaemic animal models 
have illustrated increased haematoma expansion following ICH and the proposed mechanism is 
via plasma kallikrein (PK). Binding of PK with collagen inhibits platelet aggregation, especially 
in diabetic rats. Haematoma expansion in the subarachnoid space and haematoma volume were 
significantly greater in diabetic rats in comparison with non-diabetic controls perhaps indicating 
that hyperglycaemic conditions relate with haemorrhagic expansion.
73
 Further animal models 
have underlined the role of hyperglycaemia in causing vasogenic and cytotoxic cerebral oedema 
as well as perihaematomal cell death. TNF-α and possible interleukins have been suggested (IL-
1β).74 These findings of haematoma expansion were supported by Kimura et al.70 who reported 
increased brain oedema in hyperglycaemic patients which may further contribute to the poor 
outcomes and neurological deterioration.   
 
The clinical significance of examining hyperglycaemia in ICH is to determine whether targeting 
blood glucose level may be advantageous in restricting haematoma growth, perihaematomal 
oedema and provide more favourable outcomes. This has been investigated in animal models 
where intensive blood glucose lowering therapy resulted in significantly lower intracranial 
pressure and decreased incidence of cerebral hypoxia. Neurochemistry markers such as pyruvate, 
lactate and glutamate were also significantly lower in the intensive insulin management group.
75
 
This may lead to the decreased formation of oxidation free radicals thereby ameliorating 
oxidative stress upon neurons. The role of superoxide production and oxidative stress was 
underlined through rat models where correlation with blood-brain barrier disruption was 
observed.
76
 The BBB disruption may lead to calcium influx, anaerobic glycolysis and cerebral 
parenchymal acidosis representing a possible mechanism for exacerbated neurological injury. 
Neurological complications following ICH may also occur as hyperglycaemia is associated with 
haemorrhagic transformation of ischaemic infarcts within the parenchyma of the brain.
77
  
 
2.4 The role of insulin resistance in hyperglycaemia 
Insulin is a key regulator of glucose uptake and metabolism with its actions taking effect upon 
muscle and adipose tissue. The role of insulin in carbohydrate metabolism is to accelerate 
glycolysis and induce glycogen synthesis.
78
 Insulin resistance is a pathological condition where 
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tissue sensitivity to insulin is impaired leading to dysfunctional glucose metabolism and elevated 
serum glucose levels. Potential mechanisms of insulin resistance are thought to involve defects in 
insulin signalling involving GLUT4, PIP-3 kinase and insulin responsive substrate (IRS) 
proteins.
79
 In the context of intracerebral haemorrhage the associations of insulin resistance with 
age and hypertension must be addressed.  
 
Early investigations explored the potential role of ageing in insulin resistance by comparing 
young and old subjects.
80
 Fink et al. compared insulin binding by examining adipose tissue 
biopsies in young and old patients and found no difference in binding. Insulin resistance was 
assessed using oral glucose tolerance testing with older subjects having higher levels of serum 
insulin and glucose. Based on these results, Fink et al. postulated that impaired insulin resistance 
may be related to the ageing process due to post-receptor defects. There were multiple 
limitations in this early study, with only limited baseline characteristics available to compare the 
young and old group and the small sample size restricting the statistical power. More recent 
studies suggest that insulin resistance in older patients is related to higher levels of obesity and 
visceral adiposity.
81
  
 
Metabolic syndrome and its components must also be considered, specifically the relationship 
between insulin resistance and hypertension. Metabolic syndrome refers to inter-related 
conditions of insulin resistance, hypertension, dyslipidaemia and obesity all of which are 
significant risk factors for cardiovascular and cerebrovascular disease.
82
 The relationship 
between hypertension and insulin resistance has been studied extensively through animal models, 
genetic studies and clinical investigations. Studies of glucose metabolism in the hypertensive rat 
model display impairment in insulin mediated glucose transport when compared with controls.
83
 
Genome wide scanning has also revealed potentially common loci for diabetes and 
hypertension.
84
  
 
Therefore, when studying the role of acute hyperglycaemia in intracerebral haemorrhage the 
interplay with existing insulin resistance must be considered. History of diabetes mellitus 
represents insulin resistance, however, does not account for undiagnosed diabetes mellitus, 
impaired fasting glucose and impaired glucose tolerance. In the INTERACT2 study population 
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the history of hypertension is relatively high (72.8%) and the median age is 63.3 years (see Table 
1) with these factors potentially contributing to insulin resistance. History of diabetes (11.0%) is 
also recorded and adjusted for in the analyses as will be described later, however, undiagnosed 
diabetes and impaired insulin resistance is difficult to account for. Whilst acute hyperglycaemia 
may reflect the physiological stress response to the neuronal injury of ICH, mechanisms of 
insulin resistance driven by ageing, obesity and hypertension may also be critical in the elevated 
glucose levels recorded.   
 
The relationship of insulin resistance in ischaemic stroke has been well-established; however, 
current evidence is conflicting in intracerebral haemorrhage. In ischaemic stroke insulin 
resistance is now being considered as a therapeutic target as part of secondary prevention (IRIS 
trial).
85
 This trial assessed the potential to treat insulin resistance with pioglitazone to reduce 
recurrence of vascular events. Patients with insulin resistance and a history of stroke or TIA in 
the preceding 6 months were included and pioglitazone therapy was shown to reduce recurrent 
stroke and major vascular events.
86
 Whilst the association of insulin resistance with intracerebral 
haemorrhage is still controversial, further investigation into this association is warranted.  
 
2.5 Hyperglycaemia and post-ICH outcome 
Recent studies have reported that hyperglycaemia is an independent predictor of mortality
59,70
 
and adverse functional recovery based on the modified Rankin scale (mRS).
87
 The functional 
status was characterised into favourable (mRS <3) and poor outcome (mRS ≥3). Elevated blood 
glucose was associated with poor functional recovery in non-diabetic patients, whilst increased 
mortality was found in both diabetic and non-diabetic patients. Tertile and quartile analysis of 
admission blood glucose further reveals increased risk of mild, moderate and severe handicap.
88
  
Therefore, current literature provides contrasting evidence with regards to the incidence, 
outcomes and management of hyperglycaemia in ICH. INTERACT2 with its significant cohort 
size, data on admission blood glucose and record of death and major disability over 3-months 
allows these questions to be adequately addressed.  
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Determinants of hyperglycaemia in INTERACT2 
The incidence of hyperglycaemia and association with poor outcomes in acute illness has been 
extensively described above. However, the mechanisms involved are not clearly understood. 
Specifically in ICH the relationship of hyperglycaemia with demographic, biochemical and 
clinical factors needs to be explored. Determinants of hyperglycaemia have been investigated in 
myocardial infarction, cardiac surgery and hepatic steatosis with the associated physiological 
stress resulting in elevated blood glucose levels. The uncertainty is whether hyperglycaemia is 
due to physiological stress or due to pre-existing glucose intolerance and undiagnosed DM.  
Ladeira et al.
54
 examined the predictors of hyperglycaemia in myocardial infarction with 
multivariate models showing myocardial necrosis, history of diabetes mellitus and glucose 
metabolism (HbA1c, insulin levels) to be significantly associated with hyperglycaemia. To 
effectively assess whether diabetic pathophysiology or stress hyperglycaemia is the key 
mechanism markers of glucose metabolism were studied in patients without diabetes mellitus. 
Stratifying these patients into HbA1c (<5.7, 5.-6.4, >6.4) it was found the admission blood 
glucose was significantly greater with higher HbA1c groups. This suggests that undiagnosed 
diabetes mellitus and glucose intolerance may be the driving mechanism in hyperglycaemia. 
Further, diabetes mellitus was the strongest determinant of hyperglycaemia in this investigation 
(odds ratio [OR] 27, 95 confidence interval [CI] 3.7-195.7;, P=0.001). On the other hand, the 
significant association with myocardial necrosis (measured through CK-MB and troponins) 
reported (OR 21.9, 95%CI 1.3-360.9; P=0.03) supports the stress mechanism where the more 
critical condition induces a greater glycaemic response.  
The hyperglycaemic mechanism has also been explored in patients undergoing cardiac 
catheterisation.
89
 Four groups of analysis were: patients without diabetes mellitus or acute 
coronary syndromes (ACS), diabetes mellitus and ACS, diabetes mellitus only, and ACS only. 
Again the strongest association with hyperglycaemia was seen in the diabetes mellitus group 
(OR 9.4, 95%CI 3.9-22.4; P<0.001) whilst ACS was also independently associated with 
hyperglycaemia (OR 4.6, 95%CI 2.3-9.0; P<0.001). Whilst Ladeira et al.
54
 excluded diabetic 
patients from their study, this investigation excluded patients with HbA1c ≥ 6.5% to assess the 
minimise interaction from patients with chronic hyperglycaemia and poor diabetic control.  
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Retrospective analysis of cardiac surgery patients also examined predictors of hyperglycaemia.
90
 
More comprehensive exclusion criteria was applied, excluding patients with HbA1c ≥6.5%, 
known diabetes mellitus, pre-operative random BSL ≥200 mg/dL and patients taking diabetic 
medications. Continuous BSL was monitored 4 hourly for a 72-hour period rather than baseline 
BSL used in other investigations. Results from this study showed multiple determinants of 
hyperglycaemia including: age, gender, body mass index, clinical parameters such as left 
ventricular ejection fraction and previous cardiac surgery. Pre-operative cardiogenic shock was 
another independent predictor of hyperglycaemia which supports the stress mechanism where 
activation of shock-related stress hormones may play a role in the elevated BSL. Other reported 
predictors of hyperglycaemia in cardiac surgery include ACE inhibitors
91
 and pre-existing 
metabolic syndrome
92
.   
Determinants of hyperglycaemia in acute stroke (ischaemic and ICH) include stroke severity, 
infarct size whilst there is conflicting evidence regarding the role of neuroendocrine hormones. 
Early studies divided patients into normoglycaemia, known diabetes, newly diagnosed diabetes 
and non-diabetic hyperglycaemia.
93
 Whilst no association was found with lesion site and stroke 
severity (Toronto stroke scale) was significantly greater in non-diabetic hyperglycaemic patients. 
Significant association between infarct size and hyperglycaemia has also been reported in 
ischaemic stroke.
93,94
 Previous investigations have also discussed the role of the neuroendocrine 
hormones in the stress hyperglycaemic response. O’Neill et al.95 found that insulin, glucagon, 
cortisol but not catecholamines (epinephrine, norepinephrine) were significantly associated with 
BSL, however, this was on univariate analysis with a small cohort (n=23) and part of a single-
centre study.  
The INTERACT2 study allows a similar assessment to be conducted for ICH. Whilst severity of 
AMI was linked with markers of myocardial necrosis (CKMB), in ICH haematoma 
characteristics such as volume and IVH extension represent the severity. As history of diabetes 
was recorded at admission this association can also be explored in the INTERACT2 cohort.   
Methods 
The INTERACT2 trial included 2839 patients assigned to intensive or guideline-recommended 
antihypertensive therapy. Demographic and clinical characteristics recorded at the time of 
enrolment included a history of diabetes mellitus and level of blood glucose.  Stroke severity was 
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measured using the GCS and National Institutes of Health stroke scale (NIHSS) at baseline, 24 
hours, and at Day 7 (or upon discharge from hospital if this occurred earlier). History recorded at 
baseline also included: past medical history (hypertension, heart disease, prior ICH, prior 
undifferentiated stroke) and current medications (insulin or glucose lowering therapy, aspirin or 
antiplatelet agents, warfarin or anticoagulation, antihypertensive therapy). Clinical measurements 
of systolic and diastolic BP, GCS score and demographic details of age, gender and recruitment 
centre were also recorded. Using CT analysis haematoma characteristics of haematoma volume, 
location and IVH extension were assessed.  
Baseline characteristics were summarized as mean (standard deviation [SD]) or median 
(interquartile range [IQR]) for continuous variables, and as number (%) for categorical variables.  
Collinearity and interactions between variables were checked.  Independent associations between 
baseline characteristics and level of blood glucose, defined as normoglycaemia (<6.5 mmol/L) or 
hyperglycaemia (≥6.5 mmol/L), and with a history of diabetes mellitus, were examined in 
multivariable logistic regression models with all significant baseline variables. These 
multivariable analyses were performed for the entire cohort (n = 2839) and in non-diabetic 
patients (n = 2361).  
Results 
Of the 2829 ICH patients, 176 were excluded because of missing baseline blood glucose 
measurements.  Table 1 shows the baseline characteristics of the remaining 2653 patients, which 
included 1348 (51%) with hyperglycaemia (>6.5 mmol/L) and 292 (11%) with diabetes mellitus. 
On univariate analysis hyperglycaemic patients were significantly more often female, from 
outside of China, had greater cortical haematomas, diabetes mellitus, higher SBP, greater clinical 
severity of stroke, and larger haematomas with IVH extension. No collinearity was found 
between the baseline variables.  All significant interactions (age x NIHSS ≥15, China x IVH 
extension, baseline haematoma volume x deep location of haematoma, and deep location of 
haematoma x IVH extension) were included in the multivariable analyses. This showed that 
female gender, patients outside of China, stroke severity (by NIHSS), SBP, history of diabetes, 
cortical location of haematomas, IVH extension and haematoma volume (ICH only) were 
significant independent predictors of hyperglycaemia (Table 1). In non-diabetic patients 
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independent predictors were female sex, recruitment outside of China, high NIHSS score, SBP, 
cortical location of ICH, large volume haematoma and IVH extension (Table 2).  
Discussion 
Our multivariate analysis identified the determinants of hyperglycaemia in the INTERACT2 
cohort. Key demographic predictors were females and patients recruited from outside China, 
whilst age was only significant in univariate analyses. The two important clinical parameters 
were stroke severity and baseline SBP. Univariate associations of hyperglycaemia with history of 
hypertension and heart disease did not remain after multivariate adjustment, whilst DM is found 
to be the strongest independent predictor of baseline hyperglycaemia. The critical haematoma 
characteristics that are also significant predictors are haematoma location (cortical), IVH 
extension and ICH volume.   
These results confirm previous investigation by Passero et al.
96
 (n=764) who identified 
haematoma volume, IVH extension and initial mean arterial pressure (MAP) as well as GCS 
(only in univariate INTERACT2 analyses) as independent predictors of hyperglycaemia in 
univariate analysis only without adjustment for diabetes mellitus. Fogelholm et al.
97
 found 
hyperglycaemia in non-diabetic patients was predicted by haematoma volume, midline shift of 
cerebral structures and high MAP. Our study showed significant association between 
hyperglycaemia and SBP in non-diabetic patients, confirming these earlier findings.  
IVH was also examined in INTERACT2 and aligns with previous investigation by Appelboom et 
al.
72
. This study specifically examined the relationship between IVH and hyperglycaemia with 
IVH categorised based on the IVH score
98
, a popular rating scale of clinical severity and 
prognosis in ICH. Determinants of hyperglycaemia in this study (n=104) were diabetes mellitus 
and IVH score with a linear relationship reported between admission blood glucose levels and 
the IVH score (multivariate analyses). Accordingly, greater IVH severity is associated with a 
more severe hyperglycaemic state. This may support the stress hyperglycaemia hypothesis 
whereby the driver of the glucose levels is the severity of the neurological injury. Other 
haematoma characteristics such as haematoma volume and location were not determinants of 
hyperglycaemia in multivariate analyses unlike INTERACT2 findings. Our much larger, multi-
centre investigation suggests that a number of haematoma characteristics (volume, location, IVH 
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extension) are all significantly associated with admission hyperglycaemia and need to be 
individually examined to understand the mechanism and the impact upon survival outcomes.  
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Table 2.1: Baseline characteristics by admission blood glucose in INTERACT2 cohort; multivariate analyses 
  All 
(N=2653) 
Glucose<6.5 
(N =1305) 
Glucose≥6.5(N=1348) P value 
Adjusted OR P value 
Age, median(IQR)* 63.3(54.4-73.8) 62.1(53.8-72.3) 64.5(54.9-75.1) <0.0001   
Male sex* 1655(62.4) 863(66.1) 792(58.8) <0.0001 0.74(0.62-0.88) 0.0006 
Recruited from 
China* 
1764(66.5) 943(72.3) 821(60.9) <0.0001 
0.74(0.61-0.88) 0.0009 
GCS, median (IQR) 14(13-15) 14(13-15) 14(12-15) <0.0001   
Time to 
randomisation, hours 
3.7(2.8-4.7) 3.7(2.8-4.6) 3.7(2.8-4.8) 0.54 
  
NIHSS, median 
(IQR)* 
11(6-16) 9(5-14) 12(7-16) <0.0001 
1.03(1.01-1.04) 0.0004 
Systolic BP, mmHg, 
mean(SD)* 
179.0(17.0) 177.2(16.9) 180.0(16.8) <0.0001 
1.01(1.01-1.02) 0.0001 
Diastolic BP, mmHg, 
mean±SD 
100.9±14.6 101.2±14.1 100.6±15.2 0.27 
  
History of 
hypertension* 
1928(72.8) 922(70.7) 1006(74.7) 0.0197 
  
Current use of 
antihypertensive 
therapy 
1209(45.6) 556(42.6) 653(48.5) 0.0024 
  
Heart disease* 287(10.8) 115(8.8) 172(12.8) 0.0011   
Prior intracerebral 
haemorrhage 
217(8.2) 105(8.1) 112(8.3) 0.80 
  
Prior ischaemic or 
undifferentiated 
stroke 
302(11.4) 145(11.1) 157(11.7) 0.66 
  
History of diabetes* 292(11.0) 46(3.5) 246(18.3) <0.0001 5.91(4.21-8.31) <0.0001 
Use of warfarin 
anticoagulation 
77(2.9) 31(2.4) 46(3.4) 0.11 
  
Use of aspirin or 
other antiplatelet 
agent* 
260(9.8) 95(7.3) 165(12.3) <0.0001 
  
Insulin therapy or 
glucose lowering 
treatment 
179(6.8) 31(2.4) 148(11.0) <0.0001  
 
Deep location of 
haematoma§* 
2036(83.0) 1052(86.8) 984(79.4) <0.0001 
0.51(0.40-0.65) <0.0001 
IVH Extension* 685(27.9) 264(21.8) 421(34.0) <0.0001 1.77(1.46-2.14) <0.0001 
Haematoma volume 
at baseline, mL, 
median (IQR)  
        
  
ICH* 10.9(5.7-19.5) 10.2(5.4-17.0) 11.6(6.2-21.9) <0.0001 1.01(1.00-1.02) 0.0068 
Combined 
(ICH+IVH) 
13.1(6.4-23.8) 11.6(5.9-20.0) 14.6(7.0-28.0) <0.0001 
  
Data are n(%), mean (SD), or median (IQR) 
§ Deep location refers to location in the basal ganglia or thalamus. 
P values are based on chi-squared, t-test or Wilcoxon rank sum test. 
*all significant univariate variables were put into the multivariable model. We reduced the full model by 
successively removing the nonsignificant covariates until all the remaining predictors remained statistically 
significant (P<0.05). 
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Table 2.2: Baseline characteristics by admission blood glucose in Non-diabetic Patients 
  Glucose<6.5 
(N =1259) 
Glucose≥6.5(N=1102) P value 
Adjusted OR P value 
Age, mean(SD) 62.4(12.6) 64.3(13.2) 0.0007   
Male sex 833(66.2) 634(57.5) <0.0001 0.71(0.60-0.86) 0.0003 
Recruited from China 920(73.1) 702(63.7) <0.0001 0.71(0.59-0.86) 0.0004 
GCS, median (IQR) 14(13-15) 14(12-15) <0.0001   
Time to 
randomization, hours 
3.7(2.8-4.6) 3.7(2.8-4.8) 0.35 
  
NIHSS, median 
(IQR) 
9(5-14) 12(7-17) <0.0001 
1.03(1.02-1.05) <0.0001 
Systolic BP, mmHg, 
mean(SD) 
177.2(16.9) 180.0(16.8) <0.0001 
1.01(1.01-1.02) 0.0001 
Diastolic BP, mmHg, 
mean(SD) 
101.5(14.0) 101.2(15.3) 0.0038 
  
History of 
hypertension 
884(70.3) 793(72.1) 0.33 
  
Current use of 
antihypertensive 
therapy 
523(41.6) 490(44.6) 0.15 
  
Heart disease 109(8.7) 118(10.7) 0.092   
Prior intracerebral 
haemorrhage 
100(8.0) 89(8.1) 0.90 
  
Prior ischaemic or 
undifferentiated 
stroke 
137(10.9) 116(10.6) 0.79 
  
Use of warfarin 
anticoagulation 
29(2.3) 31(2.8) 0.43 
  
Use of aspirin or 
other antiplatelet 
agent 
89(7.1) 106(9.6) 0.0243 
  
Insulin therapy or 
glucose lowering 
treatment 
6(0.5) 5(0.5) 0.94  
 
Deep location of 
haematoma§ 
1015(87.0) 790(78.1) <0.0001 
0.47(0.37-0.60) <0.0001 
IVH Extension 253(21.7) 345(34.1) <0.0001 1.81(1.48-2.20) <0.0001 
Haematoma volume 
at baseline, mL, 
median (IQR)  
10.2(5.5-17.1) 12.2(6.5-23.5) <0.0001 
1.01(1.00-1.02) 0.0093 
 
Data are n(%), mean (SD), or median (IQR) 
§ Deep location refers to location in the basal ganglia or thalamus. 
P values are based on chi-squared, t-test or Wilcoxon rank sum test. 
*all significant univariate variables were put into the multivariable model. We reduced the full model by 
successively removing the nonsignificant covariates until all the remaining predictors remained statistically 
significant (P<0.05). 
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3.3 Abstract 
Background and Purpose:  We aimed to determine associations of baseline blood glucose and 
diabetes mellitus with clinical outcomes in participants of the Intensive Blood Pressure 
Reduction in Acute Cerebral Haemorrhage Trial (INTERACT2).   
Methods:  INTERACT2 was an international prospective, open, blinded endpoint, randomised 
controlled trial of 2839 patients with spontaneous ICH (<6 hr) and elevated systolic blood 
pressure (SBP) randomly assigned to intensive (target SBP <140 mmHg) or guideline-based 
(SBP <180 mmHg) BP management.  Associations of hyperglycaemia at presentation (>6.5 
mmol/L) and combined and separate poor outcomes of death and major disability (scores of 3-6, 
3-5, and 6, respectively, on the modified Rankin scale) at 90 days were determined in logistic 
regression models.   
Results:  In 2653 patients with available data, there were 1348 (61%) with hyperglycaemia and 
292 (11%) with diabetes mellitus.  Associations of baseline blood glucose and poor outcome 
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were strong and near continuous.  After adjustment for baseline variables, the highest fourth 
(7.9-25.0 mmol/L) of blood glucose was significantly associated with combined poor outcome 
(adjusted odds ratio [aOR] 1.35, 95% confidence interval [CI] 1.01-1.80; P trend 0.015).  
Diabetes mellitus also predicted poor outcome (aOR 1.46, 95% CI 1.05-2.02; P = 0.023) though 
more important for residual disability than death on separate analysis.  
Conclusions: Hyperglycaemia and diabetes mellitus are independent predictors of poor outcome 
in patients with predominantly mild to moderate severity of ICH.  These data support guideline 
recommendations for good glycaemic control in patients with ICH.   
Clinical Trial Registration - URL: http://clinicaltrials.gov. Unique Identifier: NCT00716079 
 
3.3 Manuscript 
Introduction 
Acute ICH is the most serious and least treatable form of acute stroke
99
 for which established 
prognostic factors include clinical severity and location and volume of haematoma at 
presentation.
100
 While stress hyperglycaemia is associated with adverse outcomes in many 
medical conditions, including acute ischaemic stroke,
101,102
 traumatic brain injury
63
 and acute 
myocardial infarction,
50
 evidence specifically related to the critical condition of ICH is varied 
and conflicting due to previous studies being limited to small single centre series
72,88
 with short 
duration of follow-up.
103
 Animal models have shown that elevated BP exacerbates cerebral 
injury following ICH
104
 and have explored associations between hyperglycaemia and cerebral 
oedema.  There may be a supra-additive effect of hyperglycaemia and the hypertensive response 
in ICH on outcome. The purpose of this study was to quantify risk associations of 
hyperglycaemia and diabetes mellitus among participants of the INTERACT2.
105
 Our hypothesis 
was that hyperglycaemia is associated with poor outcome in ICH.  
Materials and Methods 
INTERACT2 was an international, multicentre, prospective, open-label, assessor-blinded end-
point, randomised controlled trial, the details of which are described elsewhere.
105 In brief, 2839 
patients with CT-confirmed spontaneous ICH within 6 hours of onset and elevated systolic BP 
(SBP, 150-220 mmHg) were randomly assigned to receive intensive (target SBP <140 mmHg 
within 1 hour) or guideline-recommended (target SBP <180 mmHg) BP lowering therapy using 
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locally available agents according to standardised protocols.  The study protocol was approved 
by the appropriate ethics committee at each participating site, and written informed consent was 
obtained from the patient or an appropriate surrogate. 
Demographic and clinical characteristics recorded at the time of enrolment included a history of 
diabetes mellitus and level of blood glucose.  Stroke severity was measured using the Glasgow 
coma scale (GCS) and National Institutes of Health stroke scale (NIHSS) at baseline, 24 hours, 
and at Day 7 (or upon discharge from hospital if this occurred earlier).  For each CT scan, 
uncompressed digital images were sent to a central analysis laboratory in DICOM format on a 
CD-ROM identified only with the patient’s unique study number.  Haematoma volumes with and 
without inclusion of any IVH component were calculated independently by trained scientists 
who were blind to clinical data, treatment, and date and sequence of scan.  This calculation was 
done with computer-assisted multi-slice planimetric and voxel threshold techniques in MIStar 
software (version 3.2) (Apollo Medical Imaging Technology, Melbourne, Australia).  Inter-
reader reliability was checked by periodic re-analysis of the scans (15%) throughout the study to 
avoid drift (intraclass correlation coefficients 0.92).   
The primary clinical outcome was death or major disability, defined by scores 3-6 on the 
modified Rankin scale (mRS) at 90 days.
106
  Secondary outcomes were separately those of death 
and major disability (mRS score of 6 and 3-5, respectively), and serious adverse events including 
early neurological deterioration (defined as an increase of ≥4 on the NIHSS or a decline of ≥2 on 
the GCS from baseline to 24 hours post-randomisation).  Primary causes of death were classified 
into 3 categories: (i) direct effects of initial ICH, defined as any death after the onset of the 
randomised ICH event in a patient who had progressive neurological deterioration and either the 
baseline or follow-up brain scan showed haematoma with mass effect, midline shift, or 
significant extension of initial haematoma in the absence of a clear extra-cranial cause for the 
death; (ii) recurrent cardiovascular event, defined by clear clinical evidence of a recurrent stroke, 
coronary vascular event, or sudden death, according to standard definitions; (iii) other causes, 
defined by clear evidence of death due to a non-neurological cause that included pneumonia, 
sepsis, or injury. 
Baseline characteristics were summarized as mean (standard deviation [SD]) or median 
(interquartile range [IQR]) for continuous variables, and as number (%) for categorical variables.  
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Collinearity and interactions between variables were checked.  Independent associations between 
baseline characteristics and level of blood glucose, defined as normoglycaemia (<6.5 mmol/L) or 
hyperglycaemia (≥6.5 mmol/L), and with a history of diabetes mellitus, were examined in 
multivariable logistic regression models with all significant baseline variables.  Curves of 
predicted 90-day outcomes according to baseline glucose level were constructed using predicted 
values and 95% confidence intervals (CI) from the univariate logistic regression models.  
Multivariable logistic regression models adjusted by all the significant and clinically important 
baseline variables as well as significant interactions were also used to determine associations of 
baseline level of blood glucose, both as continuous and categorical (fourths) variables, and 
clinical outcomes, as well as the association between a history of diabetes and clinical outcomes.  
Sensitivity analyses were conducted to examine clinical outcomes based on diagnostic thresholds 
of blood glucose for normoglycaemia, pre-diabetes, and diabetes mellitus (<6.1, 6.1–7.0, >7.0 
mmol/L, respectively).  Cox proportional hazard modelling was used to measure survival over 
90-days post-ICH.  The associations of hyperglycaemia on absolute increase in haematoma and 
perihaematomal oedema volumes over 24 hours were assessed by an analysis of covariance 
(ANCOVA) including the same adjusted variables above.  Data are presented with odds ratios 
(OR) and 95%CI.  A two sided P value <0.05 was set as the level for statistical significance.  All 
statistical analyses were performed using SAS version 9.3 (SAS institute, Cary, NC, USA). 
Results 
Of the 2829 ICH patients, 176 were excluded because of missing baseline blood glucose 
measurements (Figure 1).  Table 1 shows the baseline characteristics of the remaining 2653 
patients, which included 1348 (51%) with hyperglycaemia (>6.5 mmol/L) and 292 (11%) with 
diabetes mellitus.  After adjusting for confounding factors, hyperglyacemic patients were 
significantly more often female, from outside of China, had greater cortical haematomas, 
diabetes mellitus, higher SBP, greater clinical severity of stroke, and larger haematomas with 
intraventricular haemorrhage (IVH) extension.  Whereas patients who presented with a history of 
diabetes mellitus tended to be older, more often from outside China, had lower diastolic BP, 
greater history of hypertension, heart disease, and use of antihypertensive, antiplatelet and 
warfarin anticoagulation therapies, and with lower haematoma volume than those patients 
without diabetes mellitus (Table 2). 
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No collinearity was found between the baseline variables.  All significant interactions (age x 
NIHSS ≥15, China x IVH extension, baseline haematoma volume x deep location of haematoma, 
and deep location of haematoma x IVH extension) were included in the multivariable analyses.    
There was a strong and near continuous relationship between baseline blood glucose level and 
death or major disability (OR 1.29, 95%CI 1.19-1.40; P<0.0001) and death (OR 1.23, 95%CI 
1.12-1.37; P<0.0001) at 90 days  and they were still significant after adjusted by confounders and 
significant interactions: adjusted odds ratio [aOR] 1.11, 95%CI 1.00-1.24; P<0.0001, aOR 1.16 
95% CI (1.01-1.33); P=0.043 for death or major disability and death, respectively (Figure 2).  
Table 3 shows that the combined poor outcome of death or major disability was significantly 
greatest for the highest fourth of baseline blood glucose (aOR 1.35, 95% CI 1.01-1.80; P trend 
0.015).  Similar trends were evident for death (P trend 0.062) and major disability (P trend 
0.041).  The trends are also similar after removing the variable of randomised lowering treatment 
from the multivariate model (Table 4).  A history of diabetes mellitus (Table 5) was significantly 
associated with death or major disability (aOR 1.46, 95% CI 1.05-2.02; P = 0.023) and major 
disability (aOR 1.51, 95% CI 1.08-2.12; P = 0.017), but not for death alone (aOR 0.96, 95% CI 
0.62-1.51; P = 0.87).  For diagnostic thresholds of blood glucose, significant trend was found for 
death or major disability (P = 0.01) and major disability (P = 0.031).  In patients with admission 
blood glucose >7.0 mmol/L, there was significantly greater association with poor outcome (aOR 
1.36, 95% CI 1.08-1.71) (Table 6).  Adjusted Cox regression models  indicate increasing risks of 
death by increasing (fourths) levels of baseline blood glucose (Figure 3a), although this 
association did not appear independent of diabetes mellitus (Figure 3b). In regard to reported 
serious adverse events (Table 7), hyperglycaemic patients had significantly greater frequency of 
early neurological deterioration (16.5% vs. 13.1%; P = 0.014), death (14.4% vs. 8.9%; P 
<0.0001) and non-fatal adverse events (25.5% vs. 20.6%; P = 0.003) in comparison with 
normoglycaemic patients.  However, there was no apparent difference in the frequencies of fatal 
and non-fatal ischaemic, cardiovascular or infectious events between the two groups of patients, 
but these numbers were small.  Patients with a history of diabetes mellitus experienced 
significantly more non-fatal serious adverse events, particular of major cardiovascular events, 
during follow-up, but the frequency of early neurological deterioration or deaths from the initial 
ICH was similar to those without diabetes mellitus (Table 8).  There was a trend toward higher 
glucose levels among patients with higher baseline haematoma and perihaematomal oedema 
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volumes (Table 9 and 10, respectively). However, there was no significant difference of increase 
in either hematoma and perihaematomal oedema volumes between patients with admission 
glucose <6.5 or ≥6.5 mmol/L. These relationships are further explored in Chapter 4.  
Discussion 
This study shows that elevated blood glucose levels and diabetes mellitus both predict serious 
outcomes in patients with predominantly mild to moderate severity of acute ICH.  
Hyperglycaemia appears to influence prognosis of the acute event, increasing the risks of early 
neurological deterioration and death directly from the ICH, but without any apparent effect on 
growth in either haematoma or perihaematomal oedema over 24 hours (Chapter 4). Further, a 
near continuous association was evident between the level of blood glucose at presentation and 
the separate and combined outcomes of death and major disability over the subsequent 90 days.  
Moreover, the association was not affected by randomised BP lowering treatment. While 
diabetes mellitus was also associated with poor outcome, this appears to relate more to effects on 
residual disability and increased risks of future cardiovascular events rather than through a direct 
effect on the initial event.  
Our findings extend previous reports of elevated blood glucose being a predictor of adverse 
outcomes in ICH.
70,88,97,103
 In particular, the finding of a trend towards greater mortality from 
hyperglycaemia that was observed in Korean multi-centre study
103
 of 1387 ICH patients, but not 
with that seen in a smaller Finnish study.
97
 Sensitivity analysis of outcomes based on diagnostic 
thresholds (reference group <6.1 mmol/L) of blood glucose rather than fourths (reference group 
of 2.6–5.6 mmol/L) potentially allowed more clinically relevant glucose levels to be assessed.  
Specifically, the patient groups with admission glucose levels <6.1 and 6.1–7.0 mmol/L had less 
adverse outcomes than those with admission levels >7.0 mmol/L.   
In contrast to previous studies that have defined critical prognostic thresholds of hyperglycaemia, 
such 8
107
 or 10 mmol/L,
72
 we have shown no threshold but rather a strong continuous 
relationship between admission blood glucose and poor outcome in the INTERACT2 dataset. 
The multivariable analyses indicate that these associations are specific to hyperglycaemia rather 
than that of the pathophysiology of diabetes mellitus.  In contrast to previous studies showing 
that diabetes mellitus is an independent predictor of mortality after acute ischaemic stroke,
108
 and 
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for in-hospital
35
 and 1
36
 and 3 months
69,96,109 
time points after ICH, we did not find that diabetes 
mellitus predicted death after ICH.   
The exact pathophysiological mechanisms underlying the adverse effects of hyperglycaemia in 
ICH are yet to be elucidated. Hyperglycaemia has been shown to induce neuronal apoptosis in 
experimental ICH in adult Sprague-Dawley male rats,
110
 but other reactions from inflammatory 
(interleukin-1and tissue necrosis factor alpha)111,112 and toxic (cerebral lactate and 
lactate/pyruvate ratios)
113 
effects of oxygen free radical generation
114
 may also be important. 
Elevated white blood cells have been found to be positively correlated with glucose levels in 
ICH and are also an independent predictor of poor outcome.
115
 The leucocytosis may represent 
an inflammatory response caused by the hyperglycaemia and may exacerbate further 
neurological injury.  
Recent studies have also shown increased superoxide production, disruption of the blood-brain 
barrier,
76,116
 and enhanced cerebral oedema
74
 in hyperglycaemic rat models.  Moreover, the study 
of Parsons et al.
117
 in patients with ischaemic stroke has shown an association of hyperglycaemia 
and brain lactate and penumbral damage, quantified by magnetic resonance imaging with 
spectroscopy, which suggests there could be a similar mechanistic pathway in ICH.   
Whatever the mechanism, our data lend support guideline recommendations for good glycaemic 
control in ICH
118
 and suggest that a blood glucose level of <7.0 mmol/L may be an optimal 
therapeutic target despite the absence of randomised evidence.  In the United Kingdom Glucose 
Insulin in Stroke Trial (GIST-UK),
119
 there was no effect of glucose-potassium-insulin compared 
to saline over the initial 24 hours on mortality in 933 patients with stroke (including 114 with 
ICH) when the trial was stopped early because of slow enrollment.  Moreover, a meta-analysis of 
randomised controlled trials comparing glycemic control by insulin with usual care in patients 
with ischaemic stroke also showed no benefit regarding mortality or functional outcome and 
increased risk of hypoglycaemic events, suggesting the potential harmful effects of intensive 
glycaemic control to vulnerable ischaemic penumbra.
120
 However, there are still significant 
uncertainties regarding optimal glucose levels and glycaemic control methods in acute stroke, 
especially in ICH which distinct pathophysiological mechanisms from ischaemic stroke. 
Strengths of our study include the large and heterogeneous patient population which had rigorous 
prospective and systematic evaluations early after the onset of acute ICH.  However, as these 
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analyses were not pre-specified, they are open to chance or biased associations, and therefore the 
findings require further validation.  Another limitation is that they are based on single 
measurements of blood glucose and thus prone to regression dilution bias as well as some 
misclassification bias with respect to diabetes mellitus status since this was based only on a 
history of the condition at presentation.  Although our study had a much lower frequency of 
diabetes mellitus (11%) than has been reported in other studies (14-23%),
72,88,96
 many of the 
participants were from China where the frequency of obesity and diabetes mellitus is lower than 
in the west.  Finally, as the INTERACT studies excluded patients with a high likelihood of early 
death and planned surgical evacuation of haematoma, these findings may not be applicable to 
patients with severe ICH. 
In summary, our study has shown that hyperglycaemia has strong and continuous associations 
with poor outcomes from predominantly mild to moderate severity of ICH.  Hyperglycaemia 
appears to have a direct deleterious effect on the initial ICH, whereas diabetes mellitus reduces 
the potential for recovery and increases the risk of subsequent cardiovascular events.  In the 
absence of randomised evidence, these findings support current guidelines recommending 
treatment of hyperglycaemia in ICH.
121
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Figure 1: Patient flow in INTERACT2 study and admission blood glucose analysis  
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Figure 2: Predicted probabilities of outcome by baseline blood glucose level 
OR represents odds ratio for outcome; 95% CI represents 95% confidence interval; AOR represents adjusted odds ratio of outcome. 
Multivariate model adjusted for age, geographical region, gender, history of heart disease, history of hypertension, history of diabetes 
mellitus, use of aspirin or warfarin, baseline haematoma volume and location, intraventricular extension, baseline systolic blood 
pressure, admission National Institutes of Health stroke scale (score ≥15), randomised treatment, age x NIHSS≥15, china x 
intraventricular extension, baseline haematoma volume x deep location of haematoma, and deep location of haematoma x 
intraventricular extension. 
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Figure 3a: Cox proportional hazards regression curves for fourths of baseline blood glucose and death 
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Figure 3b: Cox proportional hazards regression curves for death according to level of presence of hyperglycaemia 
(>6.5 mmol/L) and history of diabetes mellitus (DM) 
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Table 3.1: Patients characteristics according to baseline blood glucose level 
 Baseline glucose level, mmol/L  
  
Variable 
2.60-5.59 
(N=644) 
5.60-6.49 
(N=661) 
6.50-7.90 
(N=693) 
7.91-25.0 
(N=655) 
P value 
Age, yr 62 (12) 63 (13) 65 (13) 65 (13) <0.001 
Male  436 (68) 427 (65) 411 (59) 381 (58)   0.001 
Recruited from China 487 (76) 456 (69) 422 (61) 399 (61) <0.001 
Time to randomization, hr 3.8 (2.8-4.7) 3.7 (2.9-4.6) 3.7 (2.8-4.8) 3.7 (2.8-4.7)   0.94 
Level of consciousness, GCS score 15 (13-15) 14 (13-15) 14 (12-15) 14 (12-15) <0.001 
Neurological impairment, NIHSS score 8 (4-13) 10 (6-15) 12 (7-16) 12 (7-17) <0.001 
Systolic BP, mmHg 177 (17) 177 (17) 180 (17) 182 (17) <0.001 
Diastolic BP, mmHg 102 (14) 101 (14) 100 (15.3) 100 (15)   0.49 
History of hypertension 454 (71) 468 (71) 494 (71.4) 512 (78)   0.004 
Use of antihypertensive therapy 277 (43) 279 (42) 309 (44.7) 344 (53)   0.001 
Heart disease 58 (9) 57 (9) 72 (10.4) 100 (15) <0.001 
Prior ICH 52 (8) 53 (8) 56 (8.1) 56 (9)   0.98 
Prior ischaemic / undifferentiated stroke 76 (12) 69 (10) 82 (11.9) 75 (12)   0.84 
History of diabetes mellitus* 22 (3) 24 (4) 52 (7.5) 194 (30) <0.001 
Insulin or glucose lowering treatment* 13 (2) 18 (3) 28 (4.1) 120 (18) <0.001 
Use of warfarin anticoagulation 10 (2) 21 (3) 19 (2.8) 27 (4)   0.049 
Use of aspirin or other antiplatelet agent 46 (7) 49 (7) 77 (11.1) 88 (14) <0.001 
Deep location of haematoma† 514 (85) 538 (88) 524 (81.0) 460 (78) <0.001 
IVH extension 120 (20) 144 (24) 209 (32.3) 212 (36) <0.001 
Haematoma volume, mL       
   ICH 9.0 (4.6-16.1) 11.4 (6.2-18.7) 11.5 (6.4-20.8) 11.9 (6.0-22.8) <0.001 
   Combined ICH + IVH 10.2 (5.1-18.0) 13.3 (7.1-21.8) 14.2 (7.2-27.0) 15.3 (7.0-29.1) <0.001 
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Data are n (%), mean (±SD), or median (IQR).  aOR, denotes adjusted odds ratio; BP, blood pressure; NIHSS, National Institutes of 
Health stroke scale; GCS, Glasgow coma scale; ICH, intracerebral haemorrhage; IVH, intraventricular haemorrhage. 
P values based on chi-squared, t-test or Wilcoxon rank sum test. 
*As there was a strong collinearity between history of diabetes mellitus and insulin or glucose lowering treatment, only diabetes 
mellitus was included in the multivariable analyses 
†Deep location refers to location in the basal ganglia or thalamus. 
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Table 3.2:  Baseline characteristics for ICH patients according to the presence of diabetes mellitus 
 All 
(N=2826) 
No diabetes mellitus 
(N=2521) 
Diabetes mellitus 
(N=305) 
P value 
Age 63 (54-74) 63 (54-73) 67 (60-76) <0.001 
Male 1777 (63) 1579 (63) 107 (65)   0.44 
Recruited from China    1917 (68) 1764 (70) 153 (50) <0.001 
Time to CT scan, hr 1.8 (1.2-2.7) 1.8 (1.2-2.7) 1.8 (1.3-2.9)   0.16 
NIHSS score 11 (6-15) 10 (6-15) 12 (7-16)   0.12 
Systolic BP, mmHg 179 (17) 179 (17) 180 (17)   0.32 
Diastolic BP, mmHg 101 (15) 102 (15) 97 (14) <0.001 
Heart rate, beats/min 76 (68-86) 76 (68-86) 78 (70-87)   0.057 
History of hypertension 2048 (73) 1786 (71) 262 (86) <0.001 
Antihypertensive therapy
 
1274 (45) 1069 (42) 205 (67) <0.001 
Beta-blocker 227 (8) 178 (78) 49 (16) <0.001 
Calcium-channel blocker 393 (14) 319 (13) 74 (24) <0.001 
History of heart disease 299 (11) 238 (9) 61 (20) <0.001 
Prior intracerebral haemorrhage 229 (8) 201 (8) 28 (9)   0.47 
Prior ischaemic or undifferentiated stroke 323 (11) 273 (11) 50 (16)   0.004 
Use of warfarin anticoagulation 81 (3) 63 (3) 18 (6)   0.001 
Use of aspirin or other antiplatelet agent 265 (9) 198 (8) 67 (22) <0.001 
Insulin therapy or glucose lowering treatment 183 (7) 12 (1) 171 (56)  
Deep location of haematoma* 2180 (84) 1940 (83) 240 (84)   0.84 
Left hemisphere site of haematoma 1312 (50) 1170 (50) 142 (50)   0.83 
Intraventricular extension 739 (28) 647 (28) 92 (32)   0.12 
Haematoma volume, mL      
    Haematoma alone 10.9 (5.8-19.5) 11.2 (5.9-19.7) 9.2 (4.7-16.7)   0.002 
    Combined with intraventricular haemorrhage
 
13.1 (6.5-23.8) 13.3 (6.6-23.9) 11.4 (5.6-22.8)   0.035 
Data are n (%), mean (SD), or median (IQR).  aOR indicates adjusted odds ratio; BP, blood pressure; CT, computed tomography; 
NIHSS, National Institutes of Health Stroke Scale; and ICH, intracerebral haemorrhage.  P values based on chi-squared, t-test or 
Wilcoxon rank sum test. 
*Deep location refers to location in the basal ganglia or thalamus. 
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Table 3.3: Fourths of baseline blood glucose and 3-month outcomes after acute intracerebral haemorrhage  
Outcome Fourths of glucose    Events 
OR (95%CI) 
P trend Multivariate 
Category N  n   (%) aOR (95% CI) P trend 
Death or major 
disability 
<5.6 637  268 (42) 1.0 <0.001 1.0 0.015 
5.6-6.5 650  319 (49) 1.33 (1.07-1.65)  1.07 (0.82-1.39)  
6.5-7.9 685  395 (58) 1.88 (1.51-2.33)  1.31 (1.01-1.71)  
>7.9 647  399 (62) 2.22 (1.77-2.77)  1.35 (1.01-1.80)  
         
Death <5.6 637  45 (7) 1.0 <0.01 1.0  
5.6-6.5 650  70 (11) 1.59 (1.07-2.35)  1.37 (0.88-2.12) 0.062 
6.5-7.9 685  86 (13) 1.89 (1.29-2.76)  1.16 (0.76-1.79)  
>7.9 647  107 (17) 2.61 (1.81-3.76)  1.63 (1.06-2.51)  
         
Major disability <5.6 592  223 (38) 1.0 <0.001 1.0 0.041 
5.6-6.5 580  249 (43) 1.25 (0.99-1.57)  1.04 (0.79-1.37)  
6.5-7.9 599  309 (52) 1.76 (1.40-2.22)  1.32 (1.00-1.74)  
>7.9 540  292 (54) 1.95 (1.54-2.47)  1.27 (0.94-1.72)  
OR denotes odds ratio; aOR, adjusted odds ratio; CI, confidence interval 
*adjusted for age, geographical region, gender, history of heart disease, history of hypertension, history of aspirin or warfarin use, 
history of diabetes mellitus, baseline haematoma volume and location, intraventricular extension, baseline systolic blood pressure, 
National Institute of Health stroke scale (NIHSS) score (≥15), randomised treatment, and age x NIHSS≥15, China x intraventricular 
extension, baseline haematoma volume x deep location of haematoma, and deep location of haematoma x intraventricular extension 
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Table 3.4: Quartiles of baseline blood glucose and 90-day outcomes after acute intracerebral haemorrhage (not adjusted by 
randomised BP lowering treatment) 
 
Outcomes 
Glucose (mmol/L)    Events Multivariable 
Category N  n (%) aOR (95% CI) P trend 
Death or major disability <5.6 637  268 (42) 1.0 0.016 
5.6-6.5 650  319 (49) 1.06 (0.81-1.38)  
6.5-7.9 685  395 (58) 1.31 (1.01-1.70)  
>7.9 647  399 (62) 1.35 (1.01-1.80)  
       
Death <5.6 637  45 (7) 1.0  
5.6-6.5 650  70 (11) 1.37 (0.88-2.12) 0.062 
6.5-7.9 685  86 (13) 1.16 (0.76-1.79)  
>7.9 647  107 (17) 1.63 (1.06-2.51)  
       
Major disability <5.6 592  223 (38) 1.0 0.043 
5.6-6.5 580  249 (43) 1.03 (0.78-1.36)  
6.5-7.9 599  309 (52) 1.32 (1.00-1.73)  
>7.9 540  292 (54) 1.27 (0.94-1.72)  
OR indicates odds ratio; aOR, adjusted odds ratio; and CI, confidence interval. 
*Adjusted for age, geographical region, sex, history of hypertension, heart disease, and diabetes, use of aspirin and/or warfarin use, 
baseline haematoma volume and location, intraventricular extension, baseline systolic blood pressure, National Institute of Health 
Stroke Scale (NIHSS) score (≥15), and age*NIHSS≥15, China*intraventricular extension, baseline haematoma volume*deep location 
of haematoma, and deep location of haematoma*intraventricular extension. 
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Table 3.5: Outcomes from intracerebral haemorrhage, by diabetes mellitus status  
Outcomes  n (%) OR P value aOR P value 
Death or major disability       
  No 2329 1192 (51) 1.0  1.0  
  Yes   287   186 (65) 1.76 (1.36-2.27) <0.001 1.43 (1.03-2.00) 0.035 
Death       
  No 2329   267 (12) 1.0  1.0  
  Yes   287     39 (14) 1.22 (0.85-1.74) 0.29 0.93 (0.59-1.46) 0.74 
Major disability       
  No 2062   925 (45) 1.0  1.0  
  Yes   248   147 (59) 1.79 (1.37-2.34) <0.001 1.49 (1.06-2.10) 0.023 
OR indicates odds ratio; aOR, adjusted odds ratio. 
Models were adjusted for age, geographical region, sex, history of hypertension, diabetes, and heart disease, use of aspirin and/or warfarin, 
baseline haematoma volume and location, intraventricular extension, baseline systolic blood pressure, National Institute of Health stroke scale 
(NIHSS) score (≥15), randomised treatment, and age*NIHSS ≥15, China*intraventricular extension, baseline haematoma volume*deep location of 
haematoma, and deep location of haematoma*intraventricular extension. 
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Table 3.6: Baseline blood glucose (mmol/L) by diagnostic thresholds for diabetes mellitus and 90-day outcomes after acute 
ICH  
  Glucose (mmol/L)  Events  Crude  Multivariable adjusted* 
Outcomes Category N  n (%)  OR (95% CI) P trend  aOR (95% CI) P trend 
Death or major disability <6.1 996  443 (45)  1 <0.001  1 0.010 
 6.1-7.0 655  349 (53)  1.42 (1.17-1.74)   1.13 (0.88-1.43)  
 >7.0 968  589 (61)  1.94 (1.62-1.74)   1.36 (1.08-1.71)  
Death <6.1 996  85 (9)  1 <0.001  1 0.081 
 6.1-7.0 655  70 (11)  1.28 (0.92-1.79)   0.93 (0.63-1.36)  
 >7.0 968  153 (16)  2.01 (1.52-2.67)   1.34 (0.95-1.89)  
Major disability <6.1 911  358 (39)  1 <0.001  1 0.031 
 6.1-7.0 585  279 (48)  1.41 (1.14-1.74)   1.11 (0.87-1.43)  
  >7.0 815  436 (54)  1.78 (1.47-2.15)   1.30 (1.02-1.65)  
OR indicates odds ratio; aOR, adjusted odds ratio; CI, confidence interval; ICH, intracerebral haemorrhage 
*Adjusted for age, geographical region, sex, history of hypertension, diabetes, and heart disease, use of aspirin and/or warfarin, 
baseline haematoma volume and location, intraventricular extension, baseline systolic blood pressure, National Institute of Health 
Stroke Scale (NIHSS) score (≥15), randomised treatment, and age*NIHSS ≥15, China*intraventricular extension, baseline haematoma 
volume*deep location of haematoma, and deep location of haematoma*intraventricular extension. 
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Table 3.7.  Serious adverse events, by baseline blood glucose level 
 Glucose level  
 
<6.5 mmol/L 
(N=1305) 
≥6.5 mmol/L 
(N=1348) 
 
P value 
Early neurological deterioration  168/1282 (13.1) 217/1313 (16.5) 0.014 
Non-fatal serious adverse events 269/1305 (20.6) 344/1348 (25.5) 0.003 
    Initial ICH 26/1305 (2.0) 36/1348 (2.7)  
    Cardiovascular disease 27/1305 (2.1) 37/1348 (2.7)  
      Recurrent ICH 6/1305 (0.5) 2/1348 (0.1)  
      Ischaemic/undifferentiated stroke 3/1305 (0.2) 7/1348 (0.5)  
      Acute coronary event 3/1305 (0.2) 5/1348 (0.4)  
      Other cardiovascular disease 15/1305 (1.1) 23/1348 (1.7)  
    Non-cardiovascular disease 101/1305 (7.7) 137/1348 (10.2)  
    Severe hypotension 4/1305 (0.3) 7/1348(0.5)  
Fatal serious adverse events 115/1297 (8.9) 193/1343 (14.4) <0.001 
    Initial ICH  66/1297 (5.1) 124/1343 (9.2) <0.001 
    Cardiovascular disease 12/1297 (0.9) 16/1343 (1.2) 
 
      ICH 1/1297 (0.1) 1/1343 (0.1)  
      Ischaemic/undifferentiated stroke 1/1297 (0.1) 0/1343  
        Acute coronary event 2/1297 (0.2) 2/1343 (0.1)  
        Other vascular disease 1/1297 (0.1) 3/1343(0.2)  
        Other cardiac disease 7/1297 (0.5) 10/1343 (0.7)  
    Non-cardiovascular disease 37/1297 (2.9) 53/1343 (4.0) 
 
        Renal failure 1/1297 (0.1) 3/1343 (0.2)  
        Respiratory infections 12/1297 (0.9) 14/1343 (1.0)  
        Sepsis (includes other infections) 6/1297 (0.5) 4/1343 (0.3)  
        Non-vascular medical 18/1297 (1.4) 32/1343(2.4)   
ICH denotes intracerebral haemorrhage 
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Table 3.8: Safety outcomes during 90-day follow-up after intracerebral haemorrhage, stratified by diabetes mellitus status at baseline 
  No diabetes mellitus Diabetes mellitus   
  (N=2358) (N=295) P value 
Early neurological deterioration 345/2308 (15.0) 40/285 (14.0) 0.68 
Non-fatal serious adverse events 509/2358 (21.6) 101/285 (34.6) <0.001 
    Any neurological deterioration from intracerebral haemorrhage 81/2358 (3.4) 7/285 (2.5) 
 
    Cardiovascular disease 56/2358 (2.4) 19/285 (6.7) <0.001 
        Recurrent intracerebral haemorrhage 7/2358 (0.3) 1/285 (0.4) 
 
        Ischaemic or undifferentiated stroke 10/2358 (0.4) 4/285 (1.4) 
 
        Acute coronary event 9/2358 (0.4) 1/285 (0.4) 
 
        Other cardiovascular disease 33/2358 (1.4) 14/285 (4.9) 
 
    Non-cardiovascular disease 242/2358 (10.3) 41/285 (14.4) <0.001 
    Severe hypotension 9/2358 (0.4) 5/285 (1.8) 
 
Cause of death 267/2358 (11.3) 39/285 (13.4) 0.24 
    Direct effects of primary intracerebral haemorrhage event 165/2358 (7.0) 23/285 (7.9) 0.51 
    Cardiovascular disease 21/2358 (0.9) 7/285 (2.4) 
 
        intracerebral haemorrhage Feb-58 0 
 
        Ischaemic/undifferentiated stroke Jan-58 0 
 
        Acute myocardial infarction/coronary event/other 4/2358 (0.2) 0 
 
        Other vascular disease 4/2358 (0.2) 0 
 
        Other cardiac disease 10/2358 (0.4) 7/285 (2.4) 
 
    Non-cardiovascular disease 81/2358 (3.4) 9/285 (3.1) 
 
        Renal failure 3/2358 (0.1) 1/285 (0.3) 
 
        Respiratory infections 23/2358 (1.0) 3/285 (1.0) 
 
        Sepsis (includes other infections) 9/2358 (0.4) 1/285 (0.3) 
 
        Non-vascular medical 46/2358 (2.0) 4/285 (1.4)   
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Table 3.9: Haematoma growth over 24 hours post-randomisation by glucose levels 
 Glucose <6.5 mmol/L(n=422) Glucose ≥6.5 mmol/L(n=489) P value 
 Baseline 24 hours Baseline 24 hours  
Haematoma volume (mL), mean±SD  13.4±13.3 17.7±22.9 16.9±16.6 20.4±21.1  
Haematoma growth    
   Absolute growth volume (mL), crude mean (95% CI) 4.3 (2.8-5.9) 3.4 (2.0-4.9) 0.40 
   Absolute growth volume (mL), adjusted mean* (95% CI) 6.9 (3.9-9.9) 5.4 (2.8-8.0) 0.19 
SD indicates standard deviation; and CI, confidence interval. 
*Adjusted for age, geographical region, sex, history of hypertension, diabetes, and heart disease , use of aspirin and/or warfarin, baseline 
haematoma volume and location, intraventricular extension, baseline systolic blood pressure, randomised treatment, China*intraventricular 
extension, baseline haematoma volume*deep location of haematoma, and haematoma location*intraventricular extension. 
 
  
Chapter 3: Prognostic significance of hyperglycaemia in acute intracerebral haemorrhage 
 
55 
 
Table 3.10: Growth of perihaematomal oedema over 24 hours post randomisation by glucose levels 
 Glucose <6.5 mmol/L (n=376) Glucose ≥6.5 mmol/L (n=413) P Value 
 Baseline 24 hours Baseline 24 hours  
Perihaematomal oedema volume (mL), mean±SD 2.8±3.6 5.5±7.8 3.5±4.8 6.1±8.2  
Growth of perihaematomal oedema     
   Absolute growth volume (mL), crude mean (95% CI) 2.7 (2.1-3.3) 2.6 (2.0-3.1) 0.81 
   Absolute growth volume (mL), adjusted mean* (95% CI) 3.0 (1.9-4.1) 2.6 (1.6-3.5) 0.29 
SD indicates standard deviation; and CI, confidence interval. 
*Adjusted for age, geographical region, sex, history of hypertension, diabetes, and heart disease, use of aspirin and/or warfarin, baseline 
haematoma volume and location, intraventricular extension, baseline systolic blood pressure, randomised treatment, China*intraventricular 
extension, baseline haematoma volume*deep location of haematoma, and haematoma location*intraventricular extension
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4.2 Abstract 
Background and Purpose:  Uncertain pathophysiological mechanisms underlie the adverse 
outcomes associated with hyperglycaemia in intracerebral haemorrhage (ICH).  We aimed to 
determine the relation of hyperglycaemia to haematoma characteristics among participants of 
the INTERACT2 study.  
Methods:  INTERACT2 was an international, multicentre, prospective, open, blinded 
endpoint, randomised controlled trial involving 2839 patients with ICH (<6 hr) and elevated 
systolic blood pressure (SBP) randomly assigned to intensive (target SBP <140 mmHg) or 
guideline-based (SBP <180 mmHg) BP management during 2008-2012.  Associations of 
hyperglycaemia (≥6.5 mmol/l) and haematoma volumes at baseline (in all) and 24 hours (in 
963 patients) and perihaematomal oedema volumes (in 789 patients) were determined in 
ANOVA models. 
Results:  Baseline blood glucose was recorded in 2653 (93%) patients.  Hyperglycaemic 
patients had significantly higher baseline haematoma volumes, with (14.6 vs 11.6 ml, P 
<0.0001) and without intraventricular haemorrhage (11.6 vs 10.2 ml, P <0.01), and less deep 
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(78.8% vs. 86.5%, P <0.001) and more cerebellar (5.9% vs. 1.1%, P <0.01) haematomas. 
Hyperglycaemic patients had no difference in haematoma expansion (mean adjusted, 5.1% vs 
6.8%, P =0.13) and perihaematomal oedema (mean adjusted 86.0% vs 94.1%, P =0.46) in the 
first 24 hours.  
Conclusions:  Hyperglycaemia is associated with bleeding location and greater severity of 
initial haematoma volumes in acute ICH patients, but has no clear effect on either haematoma 
expansion or early cerebral oedema.  
 
4.3 Manuscript 
Introduction 
Intracerebral haemorrhage refers to bleeding within the brain parenchyma. Significant 
morbidity and mortality has been reported following ICH with a 1-month case fatality of 
40.4% and functional independence of 12 to 39%
2
. The INTERACT2 analyses examined 
independent predictors of both death and major disability at 3 months. This showed a 
significant association between admission blood glucose and adverse outcomes (death and 
major disability) independent of diabetes mellitus (DM). Whilst DM was significantly 
associated with major disability, no association was reported with mortality alone. The 
hyperglycaemic group also experienced significantly greater neurological deterioration over 
the first 24 hours post-admission. Uncertainty exists over the mechanism underlying this 
association between hyperglycaemia, adverse outcomes and neurological deterioration.  
Specific haematoma characteristics such as haematoma volume, location, intraventricular 
haemorrhage (IVH) and cerebral oedema are associated with adverse outcomes. Haematoma 
expansion 24 hours post-ICH has been reported in a number of studies
122-125
 and occurs in 
14.3%
123
 to 38%
125
 of ICH and is independently associated with increased mortality and 
morbidity
126
. Animal models suggest that hyperglycaemia induces haematoma expansion; 
however, there is limited human data to confirm this effect
127,128
.  
Restricting haematoma growth is essential in limiting neuronal damage and perihaematomal 
oedema which is critical in the acute management of ICH. Protecting the potential 
‘penumbra’ in ICH is also a consideration; however, controversy exists regarding its 
existence. The role of the penumbra has been tested in animal models where haematoma was 
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induced through injection of autologous blood into deep white matter and measurement of 
regional cerebral blood flow (rCBF). The evidence is conflicting with earlier studies showing 
reduced rCBF
129
 and other investigations reporting no difference in rCBF pre- and post-
haematoma.
130
 Imaging studies using PET
131
 and MRI
132
 found regions of cerebral 
hypoperfusion, however, no evidence of ischaemia in the perihaematomal zone. Therefore, 
whilst limiting haematoma volume may be important there is still ongoing controversy 
regarding whether there is a salvageable penumbra in ICH. Animal models have been used to 
analyse the effects of hyperglycaemia upon the ischaemic territory by measuring lactate 
levels and hydrogen ion concentration. In these models of ischaemic stroke, hyperglycaemia 
was associated with higher levels of lactate in the ischaemic territories.
133
 There is 
uncertainty regarding these associations in intracerebral haemorrhage with the role of 
hyperglycaemia requiring further assessment. This current study aimed to investigate the 
relationship of admission hyperglycaemia with haematoma growth, IVH and cerebral oedema 
to identify a potential role of tighter glycemic control in management.  
Methods 
Trial Design 
The present study is a prospective, randomised, open-label, assessor-blinded end-point 
(PROBE), multicentre, international clinical trial (INTERACT2). From 2008 to 2012 data 
was obtained from over 140 international centres with 2826 patients being included in this 
study. Patient inclusion depended on age ≥ 18 years, blood pressure measurement between 
150 and 220 mmHg (2 systolic measurements) and CT or MRI confirmed ICH diagnosis. 
Exclusion criteria included: GCS score of 3-5, surgical intervention, structural abnormality 
causing ICH or large volume ICH. Haematoma enlargement was measured in a specific 
cohort of 963 patients with 911 having admission blood glucose data available.  
 
Baseline demographics (age, gender, ethnicity), medical history of diabetes mellitus, 
hypertension, heart disease, previous strokes and current medications (insulin, 
antihypertensives, calcium and beta blockers) were noted. We also recorded blood glucose, 
blood pressure (systolic, diastolic) and biochemical markers at admission. Admission GCS 
was used to assess level of consciousness and severity of ICH was graded using NIHSS score 
at 24 hours.  
 
CT and MRI Analyses 
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CT and MRI scans were performed at baseline. Radiological analysis was performed to 
calculate ICH volume and the presence and volume of intraventricular haemorrhage 
extension. Location of the primary ICH, presence of hydrocephalus, midline shift of cerebral 
structures was also recorded.  In a selected subset of patients, both ICH and IVH volume was 
measured at 24 ± 3 hours. These radiological scans were analysed using MIStar version 3.2 to 
calculate haematoma volume, intraventricular extension, subdural haemorrhage and other 
parameters.  
 
Statistical Analyses  
Patients were categorized into two groups based on admission blood glucose: 
normoglycaemia (0-6.5 mM) and hyperglycaemia (> 6.5 mM). The effects of admission 
blood glucose on relative and absolute changes in haematoma volume were assessed by 
means of an analysis of covariance. The relative change in haematoma volume was log-
transformed to remove skewness after the addition of the value 1.1 to eliminate negative 
values. Baseline haematoma volume, IVH presence and volume was compared between 
groups. Admission blood glucose tertiles and quartiles in relation to haematoma volume were 
also studied and the p-trend was determined.  
Haematoma growth was calculated as absolute (mL) and proportional (%). Our multivariate 
model adjusted for age, geographical region, sex, history of stroke, treatment, baseline 
haematoma volume, baseline systolic blood pressure, admission NIHSS score≥15, use of 
aspirin, use of warfarin or other anti-platelet drugs, and history of diabetes. The association 
between history of diabetes mellitus and haematoma growth was also modelled and adjusted 
for the aforementioned covariates (excluding history of DM).  
All statistical analyses were performed using SAS version 9.3 (SAS institute, Cary, NC, 
USA). A two sided P value <0.05 was set as the level for statistical significance. 
Results 
Table 1 illustrates baseline differences in haematoma characteristics between 
normoglycaemic and hyperglycaemic patients. Stroke characteristics were more severe in the 
hyperglycaemic group with greater haematoma volume (11.6 mL normoglycaemia vs. 14.6 
mL hyperglycaemia, p<0.01) and incidence of intraventricular extension (21.8% 
normoglycaemia vs. 34.0% hyperglycaemia, p<0.01). Cerebellar haemorrhage was 
significantly more frequent in hyperglycaemic patients (1.1% normoglycaemia vs. 5.9% 
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hyperglycaemia, p<0.01) whilst deep ICH was significantly less frequent (86.8% 
normoglycaemia vs. 79.4% hyperglycaemia, p<0.01). Increasing quartiles of admission blood 
glucose correspond with greater combined haematoma volumes with significant p-trend 
(Table 2).  
Diabetic patients had significantly lower haematoma volume in comparison with non-
diabetics (DM 9.2 mL vs. NDM 11.2 mL; p < 0.01) whilst there was no association with 
haematoma location or IVH extension (Table 3).  
Of the 2653 patients in the INTERACT2 study, haematoma growth was analysed in a cohort 
of 963 patients (Table 4). 52 patients without admission blood glucose measurements were 
excluded. There was no difference in haematoma growth within the hyperglycaemic group. In 
hyperglycaemic patients: adjusted haematoma growth (normoglycaemic 6.8 ml (95%CI 4.3-
9.2) vs. hyperglycaemic 5.1 ml (95%CI 3.0-7.2); p = 0.46) and mean adjusted ICH+IVH 
growth [normoglycaemic 9.2 ml (95%CI 5.5-12.8) vs. hyperglycaemic 6.9 ml (95%CI 3.8-
10.0); p = 0.17] showed no difference.  
Similarly, there was no difference in perihaematomal oedema expansion over 24 hours 
between hyperglycaemic and normoglycaemic patients [hyperglycaemic group: 2.8 ml 
(95%CI 2.0-3.5), normoglycaemic group: 3.3 ml (95%CI 2.4-4.2); p = 0.19)] (Table 6). There 
was also no difference found between diabetic and non-diabetic patients [DM 6.2 ml (95%CI 
2.5-9.9) vs. NDM 5.7 ml (95%CI 3.3-8.1); p = 0.79] (Table 5).  
Discussion 
The present study examined radiological analyses following ICH and considered the effect of 
admission hyperglycaemia and diabetes mellitus. Baseline radiological characteristics 
illustrated that patients with elevated blood glucose at admission had significantly higher 
haematoma volume and IVH volume. In contrast, multivariate analyses showed diabetic 
patients had significantly lower haematoma volume. Haematoma growth and cerebral 
oedema growth at 24 hours were hypothesised as mechanisms for the previously reported 
neurological deterioration, however, no association was found with admission 
hyperglycaemia or history of diabetes mellitus.  
This study found that admission hyperglycaemia is correlated with more severe ICH 
characteristics, such as haematoma volume and IVH extension, in line with existing 
literature
69,97
. Quartiles of admission blood glucose displayed a significant p-trend with 
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respect to haematoma volume and admission blood glucose >6.5mM was significantly 
associated with incidence of IVH extension. Haematoma expansion and cerebral oedema 
have also been previously linked with hyperglycaemia with future potential to examine this 
relationship in the INTERACT2 cohort
73,127,128
.  
Cerebellar haemorrhages were significantly more frequent in hyperglycaemic patients whilst 
deep haematomas (thalamus and basal ganglia) were less frequent. Previous data has shown 
that cerebellar haemorrhage in hyperglycaemic patients is associated with increased severity 
with more frequent intraventricular extension, brainstem compression, hydrocephalus and 
larger haematoma diameter
59
. These parameters are all predictors of adverse outcomes 
following cerebellar haemorrhage
134
. Associations with diabetes mellitus were also explored 
to assess if diabetic patients were predisposed to haematoma in specific locations. However, 
no specific regions were identified (Table 4.3). ICH location analysis performed by Zhang et 
al.
135
, examined deep and lobar ICH and the admission blood glucose levels for these specific 
ICH sub-types. When comparing the sub-types no significant difference in admission blood 
glucose was reported, unlike our findings where patients with deep ICH were less likely to 
present with hyperglycaemia.  
With hyperglycaemic patients more likely to have cerebellar haemorrhage, specific 
complications must be considered. The risk of brainstem herniation is increased in cerebellar 
haemorrhage with data showing significantly greater one-week mortality in such cases
136
. 
Whilst this analysis was not performed in INTERACT2, the association with hyperglycaemia 
would assist in understanding the linking mechanisms. Potentially, cerebellar injury would 
disrupt neuronal processing and coordination of inputs which may explain the clinical 
deterioration observed over 24 hours and longer term adverse outcomes at 3 months.   
I noted that patients in the hyperglycaemic group had more severe ICH characteristics such as 
haematoma volume and IVH extension in line with existing literature
69,97
. Quartiles of 
admission blood glucose (Table 2) displayed a significant p-trend with respect to haematoma 
volume. This is in line with previous findings where significantly higher ICH volume has 
been reported in patients with admission hyperglycaemia
69,137
.  
Admission hyperglycaemia was also significantly associated with incidence of IVH extension 
and significantly greater IVH volume at admission. This relationship between admission 
blood glucose and IVH score was investigated by Appelboom et al.
69
. As previously 
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discussed, the linear correlation supports the stress hyperglycaemia hypothesis whereby more 
severe neurological injury results in greater hyperglycaemic response.  
Currently there is limited evidence regarding the relationship between haematoma expansion 
and admission hyperglycaemia. Kazui et al.
128
 reported that the interaction of systolic blood 
pressure (>200 mmHg) with both fasting plasma glucose and HbA1c were independent 
predictors of haematoma enlargement. Whilst this was a much smaller study (n=186) it 
questioned the potential role of hypertension and DM in inducing ICH growth. HbA1c was 
used as a parameter for DM, whilst elevated fasting plasma glucose was studied to indicate 
stress hyperglycaemia. Another study recorded blood glucose levels 5 times over 3 days 
following admission and categorised patients into increasing and declining levels
99
. In 
patients with increasing blood glucose association was found with haematoma expansion and 
perihaematomal oedema expansion.  
My hypothesis that hyperglycaemic patients would have significantly greater haematoma 
growth was also extrapolated from studies involving ischaemic stroke which demonstrated 
that hyperglycaemia was significantly associated with haemorrhagic transformation in the cat 
model
138
, rats
139,140
 and humans
43
. However, unlike these proposed mechanisms and previous 
findings the current study displayed that admission hyperglycaemia and DM held no 
association with haematoma growth.  
Animal models illustrated profound cerebral oedema with hyperglycaemia following ICH
74
. 
However, these experimental findings do not translate to the current investigation where no 
association was found between admission blood glucose and cerebral oedema at 24 hours. 
My results for perihaematomal oedema and haematoma expansion are in line with the smaller 
study by Feng et al.
141
 where no association was reported with hyperglycaemia. This earlier 
investigation used mean glucose levels over 72-hours which illustrate the effect of prolonged 
elevation in BSL upon neuronal injury.  
The findings in the current study are in direct contrast with the investigation by Liu et al.
73
 
where DM was modelled in rats using streptozotocin. In this experimental model, plasma 
kallikrein was identified as a central mediator in increasing haematoma growth and was 
therefore used to induce expansion.  This animal model tested whether DM or 
hyperglycaemia was the underlying factor in haematoma expansion and found that 
normalizing blood glucose with insulin prior to ICH resulted in significantly lower 
haematoma expansion. Furthermore inducing hyperglycaemia in NDM rats resulted in 
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increased haematoma growth. Hyperglycaemia amplified the action of kallikrein in inhibiting 
platelet aggregation thereby facilitating greater haematoma expansion. The increased plasma 
osmolality caused by increased blood glucose further contributed to haematoma growth. 
These findings indicated the potential use of insulin therapy to maintain tight glucose control 
in the acute management of ICH.  
Broderick et al.
127
 studied determinants of haematoma enlargement (n=353) and also found 
that serum blood glucose was significantly associated with greater ICH growth (p=0.02) and 
ICH+IVH growth (p=0.0306). Although statistically significant, this study could not 
demonstrate whether admission blood glucose was a causative factor or a marker of 
haematoma growth.  
A number of mechanisms have been reported involving hyperglycaemia, haematoma 
expansion and neuronal damage. Badjatia et al.
142
 studied subarachnoid haemorrhage (SAH) 
patients and found a positive association between mean blood glucose and the incidence of 
vasospasm. Patients who experienced vasospasm after SAH presented with significantly 
higher admission blood glucose. Vasospasm may exacerbate bleeding and has been proposed 
as part of the pathophysiology linking hyperglycaemia and haematoma expansion.  
Animal models have illustrated that hyperglycaemia promotes superoxide generation and 
blood-brain barrier disruption leading to exacerbation of haemorrhage and increased 
haematoma volume
76
. An experimental Sprague-Dawley rat model has also established the 
role of aquaporin-4 (AQP-4) in exacerbating ICH
116
 with downregulation noted in 
hyperglycaemic rats. Further, hyperglycaemia was positively associated with severe BBB 
disruption, as well as increased brain water content
74
 and vasogenic oedema
116
. Whilst these 
mechanisms may contribute to the significantly greater baseline ICH volume in 
hyperglycaemic patients, the link with haematoma growth was not confirmed in the present 
study.  
The current investigation illustrates the complete opposite as hyperglycaemic patients had 
lower median haematoma growth in terms of absolute (mL) and proportional growth (%). 
This was seen for ICH and ICH+IVH. The INTERACT2 analyses is the first large scale (911 
patients) human study analysing the relationship between hyperglycaemia and haematoma 
expansion. However, the results of the present study do not align with experimental animal 
models.  
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Previous human studies have evaluated the pro-thrombotic effect of hyperglycaemia and 
these factors may be involved in ICH. Specifically, hyperglycaemia accelerates the rate of 
thrombus formation and coagulation via the collagen and thrombin pathway
143,144
. 
Intravenous endotoxin administration has also been used to simulate the inflammatory state
145
 
and in hyperglycaemic patients (12 mM) coagulation was significantly higher. Similarly 
hyperglycaemia and platelet function have been studied in the context of acute coronary 
syndrome
144
. Hyperglycaemic patients had significantly higher formation of thrombin-
antithrombin complexes in comparison with normoglycaemic patients whilst platelet 
activation markers were also significantly elevated. These studies suggest that 
hyperglycaemia in acute medical conditions is associated with increased platelet function and 
coagulation. In the context of ICH this may result in coagulation of haematoma thereby 
limiting haematoma growth by decreasing bleeding over 24 hours.  
My findings illustrate the positive association between hyperglycaemia and baseline 
haematoma volume, however, patients with DM showed an unexpected association. Baseline 
haematoma volume was significantly lower in diabetic patients. This is in direct contrast to 
the significantly greater haematoma volumes seen in hyperglycaemic patients. Further, in 
diabetic patients haematoma growth was higher in the DM group with marginal significance 
(p=0.11). Therefore, we report directly contrasting associations of baseline haematoma 
volume with DM and admission blood glucose. This suggests distinct pathophysiological 
pathways in stress hyperglycaemia and diabetes mellitus.  
However, both DM and admission hyperglycaemia hold no association with haematoma 
growth. Existing literature has established that DM is responsible for a hypercoagulable 
state
146-148
. Specifically, diabetic patients present with increased concentration of clotting 
factors and von Wildebrand factor, increased platelet aggregation and impaired fibrinolysis. 
The lack of association between DM and haematoma growth may also be related to levels of 
plasminogen activator inhibitor 1 (PAI-1). Elevated PAI-1 has been found in DM
149-152
 and 
although this increases the risk of macrovascular complications (acute ischaemic stroke, acute 
myocardial infarction) it may also play a role in limiting continued bleeding following ICH 
thereby restricting haematoma growth.  
This investigation represents one of the largest cohorts of ICH patients analysed for 
haematoma volume, location and IVH (2653 patients) as well as haematoma growth (963 
patients). However, certain limitations need to be addressed. Although blood glucose was 
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only measured upon admission, continuous measurement to calculate persistent 
hyperglycaemia may have been more effective in elucidating the mechanism with haematoma 
growth. Undiagnosed diabetic patients were not included. Other studies have also examined 
brain oedema and total brain water content to elicit the effect of hyperglycaemia upon 
perihaematomal regions. This may be an area that could be further analysed. The limitations 
of secondary analysis are also present in our investigation.  
Conclusions 
In conclusion, my secondary analysis revealed that patients with admission hyperglycaemia 
had more severe characteristics relating to their ICH. This included significantly higher 
haematoma volume and IVH extension. However, haematoma growth and cerebral oedema 
were not associated with admission hyperglycaemia or history of diabetes mellitus. Whilst 
further investigation is required, at this stage our study indicates that tight blood glucose 
control is not required to limit haematoma expansion. 
  
Chapter 4: Hyperglycaemia and haematoma parameters in intracerebral haemorrhage 
 
66 
 
Results 
Table 4.1: Haematoma Characteristics in Normoglycaemic and Hyperglycaemic patients 
  All 
(N=2653) 
Glucose<6.5 
(N =1305) 
Glucose≥6.5 
(N=1348) 
P 
value 
Haematoma Location     
    Lobar 251(10.2) 112(9.2) 139(11.2) 0.11 
    Deep 2025(82.6) 1048(86.5) 977(78.8) <0.01 
    Cerebellar 86(3.5) 13(1.1) 73(5.9) <0.01 
Ventricular 11(0.5) 4(0.3) 7(0.6)   
Brainstem 77(3.1) 35(2.9) 42(3.4) 0.48 
Deep location of haematoma§– no./total no. (%) 2036(83.0) 1052(86.8) 984(79.4) <0.01 
Left hemisphere site of haematoma- no./total no. 
(%) 
1223(49.9) 590(48.7) 633(51.1) 0.24 
IVH Extension - no./total no. (%) 685(27.9) 264(21.8) 421(34.0) <0.01 
Haematoma volume at baseline, mL, median 
(IQR)  
        
ICH 10.9(5.7-19.5) 10.2(5.4-17.0) 11.6(6.2-21.9) 0.01 
    IVH 0.0(0.0-0.8) 0.0(0.0-0.0) 0.0(0.0-2.4)   
    Combined 13.1(6.4-23.8) 11.6(5.9-20.0) 14.6(7.0-28.0) <0.01 
     
§ Deep location refers to location in the basal ganglia or thalamus. 
P values are based on chi-squared, t-test or Kruskal-Wallis test 
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Table 4.2: Baseline haematoma volume stratified by glucose (quartiles) 
 
 
 
 
 
Table 4.3: Haematoma Characteristics in DM and NDM 
 All 
(N=2826) 
Non-Diabetes Mellitus 
(N =2521) 
Diabetes Mellitus 
(N=305) 
P Adjusted OR 
 (95% CI) 
P 
Location– no (%)       
    Lobar 260(10.0) 228(9.8) 32(11.2)    
    Deep 2168(83.0) 1930(83.0) 238(83.2)    
    Cerebellar 89(3.4) 80(3.4) 9(3.2)    
Ventricular 12(0.5) 10(0.4) 2(0.7)    
Brainstem 80(3.1) 75(3.2) 5(1.8)    
Deep location of haematoma§– no./total 
no. (%) 
2180(83.5) 1940(83.4) 240(83.9) 0.84   
Left hemisphere site of haematoma - 
no./total no. (%) 
1312(50.3) 1170(50.3) 142(49.7) 0.84   
IVH Extension - no./total no. (%) 739(28.3) 647(27.8) 92(32.2) 0.12   
Haematoma volume at baseline, mL, 
median (IQR)  
      
    ICH 10.9(5.8-19.5) 11.2(5.9-19.7) 9.2(4.7-16.7) 0.03 1.01(1.0-1.02) 0.01 
    IVH 0(0-0.8) 0(0-0.6) 0(0-1.9)    
    Combined 13.1(6.5-23.8) 13.3(6.6-23.9) 11.4(5.6-22.8) 0.06   
  
 Q1 Q2 Q3 Q4 
Haematoma volume at baseline, mL, 
median (IQR) 
 
 
   
ICH 9.0(4.6-16.1) 11.4(6.2-18.7) 11.5(6.4-20.8) 11.9(6.0-22.8) 
    Combined(ICH+IVH) 10.2(5.0-18.0) 13.3(7.1-21.8) 14.2(7.2-27.0) 15.3(7.0-29.1) 
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Table 4.4: Haematoma Growth parameters at 24 hours post randomisation, by admission blood glucose 
 
All 
(N=911) 
Glucose<6.5(N=422) Glucose≥6.5 (N =489) 
Absolute (mls) / 
proportional (%) less in 
patients with glucose≥6.5 
(95% CI) 
P Value 
Haematoma volumes, baseline to 24 hours Baseline 24 hours Baseline 24 hours Baseline 24 hours   
Haematoma (ml), mean unadjusted (SD) 15.3±15.3 19.2±22.0 13.4±13.3 17.7±22.9 16.9±16.6 20.4±21.1   
Haematoma + IVH (ml), mean unadjusted (SD) 17.7±16.9 23.2±29.5 14.9±14.6 21.1±33.3 20.1±18.4 25.0±25.7   
Haematoma growth 
    Growth (ml), mean unadjusted (95%CI)  4.3(2.8-5.9) 3.4(2.0-4.9) 0.9(-1.2-3.0) 0.40 
    Growth (ml), mean adjusted* (95% CI)  6.8(4.3-9.2) 5.1(3.0-7.2) 1.7(-0.5-3.9) 0.13 
    Growth (%), median unadjusted (95% CI)  19.6%(13.6-25.8%) 17.3%(11.8-23.0%) 2.2%(-6.5-10.8%) 0.59 
    Growth (%), median adjusted (95% CI)   29.2%(19.2-40.0%) 25.7%(17.3-34.6%) 3.6%(-5.6-12.7) 0.46 
Haematoma + IVH growth      
    Growth (ml), mean unadjusted (95%CI)  6.2(3.9-8.5) 4.9(2.8-7.0) 1.2(-1.9-4.4) 0.43 
    Growth (ml), mean adjusted* (95% CI)  9.2(5.5-12.8) 6.9(3.8-10.0) 2.3(-1.0-5.6) 0.17 
    Growth (%), median unadjusted (95% CI)  22.1%(15.8-28.7%) 19.1%(13.4-25.1%) 2.8%(-6.1-11.7%) 0.51 
    Growth (%), median adjusted (95% CI)   34.9%(24.1-46.6%) 29.5%(20.6-39.1%) 5.4%(-4.4-15.1%) 0.29 
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Table 4.5: Haematoma Growth parameters at 24 hours post randomisation, by diabetes mellitus status 
 All 
(N=963) Non-Diabetes Mellitus 
 (N =833) 
 
Diabetes Mellitus (N 
=130) 
 Absolute (mls) / 
proportional (%) 
less in patients 
with IVH(95% CI) 
P 
Value 
Haematoma volumes, baseline to 24 hours Baseline 24 hours Baseline 24 hours  Baseline 24 hours    
Haematoma (ml), mean unadjusted (SD) 15.4±15.3 19.4±22
.2 
15.6 ±15.4 19.4 ± 22.5  14.2±14.9 19.0±20.
3 
   
Haematoma + IVH (ml), mean unadjusted 
(SD) 
17.8±17.0 23.5±29
.9 
17.9±16.9 23.5±30.3  17.1±17.4 24.0±26.
8 
   
Haematoma growth                                                                                                         24 hours minus baseline                 24 hours minus baseline 
    Growth (ml), mean unadjusted (95%CI)  3.8(2.7-4.9)  4.8(2.0-7.6)  -0.9(-3.9-2.1) 0.54 
    Growth (ml), mean adjusted* (95% CI)  5.7(3.3-8.1)  6.2(2.5-9.9)  -0.5(-3.8-2.9) 0.79 
    Growth (%), mean unadjusted (95% CI)  17.0%(12.8-21.3%)  26.7%(15.5-38.8%)  -10.4(-25.6-4.8) 0.11 
    Growth (%), median adjusted (95% CI)   24.9%(15.4-35.2%)  29.5%(14.8-46.0%)   0.52 
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Table 4.6: Cerebral oedema parameters at 24 hours post randomisation 
 Glucose<6.5(N=376) Glucose≥6.5 (N =413) P Value 
Cerebral oedema volume, baseline to 24 hours Baseline 24 hours Baseline 24 hours  
Cerebral oedema (ml), median unadjusted (IQR) 1.7(0.8-3.5) 3.3(1.5-6.2) 2.0(1.0-3.9) 3.7(1.8-7.1)  
   Absolute  Growth (ml), mean unadjusted (95%CI) 2.7(2.1-3.3) 2.6(2.0-3.1) 0.81 
    Growth (ml), mean adjusted* (95% CI) 3.3(2.4-4.2) 2.8(2.0-3.5) 0.19 
   Relative  Growth (%), mean unadjusted (95% CI) 85.2(71.1-100.3) 74.3(61.7-87.9) 0.28 
    Growth (%), mean adjusted (95% CI)  94.1(71.6-119.5) 86.0(67.0-107.1) 0.46 
Multivariate Model adjusted for age, geographical region, sex, history of stroke, history of hypertension, treatment, baseline haematoma volume, IVH 
extension, baseline systolic blood pressure, and history of diabetes. 
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Chapter 5: Discussion and concluding remarks  
 
 
Conclusions from Analyses 
My investigation examined admission hyperglycaemia in ICH specifically determining 
incidence, independent predictors, associations with outcome (primary and secondary) and 
haematoma parameters, relationship with diabetes mellitus and potential underlying 
mechanisms.  
From baseline data I analysed demographic factors, clinical parameters and haematoma 
characteristics (volume, location, IVH extension) that were independent predictors of 
admission hyperglycaemia. In multivariate analysis (n=2653) after adjusting for all 
significant variables of univariate analysis and clinically significant interactions, the strongest 
independent predictor for hyperglycaemia was diabetes mellitus (aOR 5.91 95%CI 4.21-8.31, 
P<0.0001) (Table 2.1). To minimise the confounding effect of diabetes mellitus, independent 
predictors of hyperglycaemia in the non-diabetic patients (n=2361) were also determined 
(Table 2.2).   
Demographics such as gender (females) and patients recruited outside of China were 
determinants of hyperglycaemia in the complete and non-diabetic analyses. Significant 
association was also present between hyperglycaemia and ICH severity as determined by the 
NIHSS score. Severity is also reflected through haematoma parameters with haematoma 
volume and IVH extension being significant predictors of hyperglycaemia. This analysis in 
non-diabetic patients illustrates the potential stress hyperglycaemic mechanisms involved 
outside of the diabetic effect. Hyperglycaemic patients were also found to have significantly 
fewer deep haematomas when compared to normoglycaemic patients. This baseline analysis 
of haematoma characteristics directed my research into a more extensive examination of ICH 
parameters (Chapter 4).  
In the hyperglycaemic group, haematoma volume was significantly greater at baseline. To 
further examine if there was an incremental trend, I separated the cohort into quartiles by 
admission blood glucose. Increasing quartiles of blood glucose were associated with greater 
median ICH and combined (ICH + IVH) volume (Table 4.2).  
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The significance of haematoma location with potential mechanisms and suggestions for 
future studies 
Baseline analysis showed association between hyperglycaemia with superficial territory of 
ICH. I performed further location analysis to investigate the mechanism of hyperglycaemia. 
If certain haematoma territories, responsible for glucose metabolism, were more commonly 
affected in the hyperglycaemic group this would potentially suggest the underlying 
mechanism. I examined associations with lobar, cerebellar and deep haematomas. 
Hyperglycaemic patients were more likely to have cerebellar (5.9% hyperglycaemic group 
vs. 1.1% normoglycaemic group) and superficial/cortical haematomas whilst deep and 
thalamic haematomas were significantly less frequent. 
Cerebellar haemorrhage is associated with poorer outcomes and significant long-term 
morbidity and mortality. Due to anatomical location, cerebellar haemorrhage can lead to 
ventricular and brainstem compression. Involvement of the fourth ventricle can accelerate 
elevation in intracranial pressure thereby limiting cerebral perfusion and exacerbating 
neuronal injury. Cerebellar haemorrhage can also cause brainstem compression with the 
potential for trans-tentorial herniation with a smaller study (n=42) showing 60% of patients 
exhibiting radiological signs of brainstem compression and herniation.
153
 Determinants of 
outcome in cerebellar haemorrhage include haematoma volume, diameter and initial GCS 
score. Poor functional recovery and significant mortality at 6 months has been previously 
reported.
154,155
 Data assessing hyperglycaemia in cerebellar haemorrhage has been limited; 
however, the investigation by Wu et al.
59
 determined independent predictors of outcome. 
They reported haematoma diameter and admission hyperglycaemia (> 7.8 mmol/L) to be 
predictive of mortality at discharge. In the 86 patients with cerebellar haemorrhage in 
INTERACT2 cohort, 84.9% presented with admission hyperglycaemia (n=73). Further 
investigation of hyperglycaemia specifically in cerebellar haemorrhage can be performed to 
examine associations with haematoma parameters (volume and diameter) and complications 
(brainstem compression, trans-tentorial herniation). This may also reveal potential 
mechanism for poorer outcomes in hyperglycaemic ICH patients.  
A limitation of my approach was that the categorisation of location was too general. More 
specific categorisation would underline potential critical neuroanatomical regions affected by 
ICH and involved in dysfunction of glucose metabolism. Determining the involvement of 
regions such as the hypothalamus may provide further understanding for the cause of 
elevated blood glucose levels. The hypothalamus regulates glycaemic control with 
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specialised glucose sensing neurons involved in insulin regulation at the pancreatic islet cells 
as seen in animal models.
156
 Glucose kinase activity in the hypothalamus mediates processing 
of glucose and initiates the insulin response via the neural-islet axis. Chronic down-regulation 
of these hypothalamic insulin receptors lead to glucose intolerance and pancreatic islet cell 
impairment reflecting their role in glucose metabolism in the rat model.
157
 Distinct glucose-
sensitive regions in the hypothalamus that have been identified include the ventromedial
158
, 
lateral and arcuate nucleus
159
. The dorsal vagal complex in the brainstem also contains 
glucose sensitive neurons involved in glucose homeostasis
160
 with recent studies reporting the 
role of the nucleus of solitary tract in detecting circulating glucose. Analysing the specific 
location of ICH in patients with hyperglycaemia may indicate if these glucose-critical regions 
are damaged and thereby responsible for the hyperglycaemic state rather than a generalised 
physiological stress response.  
Blood glucose level is also affected by autonomic activation and neurohormonal signalling. 
The release of adrenocorticotropic hormone (ACTH) from the anterior pituitary induces 
cortisol release via the hypothalamic-pituitary-adrenal axis (HPA axis). The net effect is a 
hyperglycaemia through increased hepatic gluconeogenesis and decreased peripheral uptake 
of glucose. Sympathetic activation will also cause hyperglycaemia through increased serum 
adrenaline and noradrenaline. Damage to structures involved in autonomic pathways and the 
HPA axis may also explain the hyperglycaemic response. Whilst this could not be determined 
in the present study, more specific location analysis may allow this. In the INTERACT2 
analyses, cortisol and catecholamine levels were not recorded. An earlier study by van 
Kooten et al. measured catecholamine levels as a surrogate marker for physiological stress 
and found no association with blood glucose and suggested that hyperglycaemia was not a 
result of the stress response
161
. A limitation of this analysis is that plasma catecholamine 
levels are not an accurate marker of sympathetic nervous system activation. The plasma 
concentration of catecholamines only represents a proportion of total neurotransmitter 
released and plasma levels are also affected by local neuronal uptake.
162
 Catecholamine 
levels are also determined by physiological stimuli such as breathing, emotional stimuli and 
body positions (standing, squatting). These factors may have contributed to the lack of 
association found in this observational study. The statistical significance of this study was 
also limited by its small cohort size (n=91). Further investigation is required in determining 
the association of stress hormones (catecholamines, cortisol) with blood glucose levels as this 
will highlight the magnitude of the stress component in hyperglycaemia. 
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Mechanism driving hyperglycaemia: stress response or diabetic pathophysiology 
The primary question in terms of the mechanism is whether the driver of hyperglycaemia is 
the severity of the ICH (by volume, location, IVH extension) or if an inherent dysglycaemic 
state caused by diabetes (diagnosed or undiagnosed). I also aimed to determine if 
hyperglycaemia acts as a marker of this physiological stress and diabetic pathophysiology or 
whether it exacerbates neuronal injury. From the baseline characteristics and determinants of 
hyperglycaemia, a significant association was observed with history of diabetes (n=292). 
Undoubtedly diabetic patients would be more prone to hyperglycaemia due to impaired 
glucose homeostasis mechanisms and accordingly 84.2% of diabetics in our study presented 
with admission hyperglycaemia. However, there were still 1102 non-diabetic hyperglycaemic 
patients in our analyses. Within this group there would be a proportion of undiagnosed 
diabetics and patients with pre-diabetes (impaired fasting glucose and impaired glucose 
tolerance) which must be accounted for. The determinants of the hyperglycaemia in the non-
diabetics were parameters of ICH severity (haematoma volume and location, IVH extension, 
NIHSS score) as well as demographic differences. Therefore, there are multiple mechanisms 
at play in the presentation of hyperglycaemia. There is the contribution of diabetic 
pathophysiology and potentially undiagnosed diabetes. However, outside of this effect the 
severity of the haematoma is the other significant driver highlighting the role of the stress 
response.  
The role of BP lowering in hyperglycaemic and diabetic patients: a potential treatment 
effect 
The INTERACT2 study compared intensive and guideline based BP lowering therapy in 
acute ICH in terms of long-term outcome (3-month death or major disability). The main 
paper
105
 examined primary (death or major disability) and secondary outcomes (mRS score, 
health-related quality of life, fatal and non-fatal adverse events). It also compared the 
treatment effect across 8 subgroups: age, region (from or outside China), time to 
randomisation, baseline SBP, history of hypertension, baseline NIHSS score, baseline 
haematoma volume and location. Across all subgroups there was no significant difference in 
primary or secondary outcomes.  
In this analysis, the treatment effect with admission blood glucose and history of diabetes 
mellitus was not studied. However, there is the potential to revisit these earlier models and 
assess the potential treatment effect in the hyperglycaemic group. This would involve 
comparing hyperglycaemic patients treated with guideline and intensive therapy and 
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reviewing whether there are differences in primary and secondary outcomes. More recent 
INTERACT2 analyses explored the efficacy of BP reduction of SBP in hypertensive patients 
by comparing minimal (<10 mm Hg), moderate (10-20 mm Hg) and large (≥ 20 mm Hg) 
changes in SBP and determining association with poor outcomes (death or major 
disability).
163
 This showed that large reductions in SBP during the first hour and maintained 
over 7 days were less associated with poor outcome in comparison with minimal reductions 
(<10 mm Hg). There is also the potential to assess how hyperglycaemic patients respond to 
different degrees of BP reduction.  
At baseline, the hyperglycaemic patients presented with significantly greater SBP 
(P=0.0001). It is critical to evaluate the differences between guideline and intensive therapy 
and to determine how aggressively blood pressure should be lowered in this important subset 
of ICH patients. The treatment effect must also be explored in the diabetic patients. The 
microvascular complications of diabetes are well documented and the overlap between 
diabetes and hypertension is known. Both are significant cardiovascular and cerebrovascular 
risk factors and accelerate atherosclerosis. Therefore, exploring potential treatment effects in 
both hyperglycaemic and diabetic patients will provide valuable data regarding the 
therapeutic approach to these patient subsets and whether a distinct BP lowering strategy is 
required when treating ICH patients presenting with diabetes or admission hyperglycaemia.  
Association between admission hyperglycaemia and outcomes  
After establishing baseline characteristics and determinants of hyperglycaemia, I investigated 
the associations with primary and secondary outcomes. Primary outcomes were death or 
major disability, death alone, and major disability alone, at 90 days whilst secondary 
outcomes were neurological deterioration over the first 24 hours, and fatal and non-fatal 
adverse events.  
Existing data on hyperglycaemia in ICH and associations with outcomes is represented in 
Table 1 and 2. The majority of data evaluates outcomes either at discharge or in the first 
month post ICH with limited data on longer term follow-up. However, the majority of these 
studies report significant association with poorer survival in the hyperglycaemic patients. Our 
findings at 3-months build upon the existing literature with the advantage of INTERACT2 
analyses being the significantly larger cohort size, multi-centre data and comprehensive study 
design.  
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Our multivariate model adjusted for all significant baseline variables and clinically 
significant interactions and patients were divided based on admission blood glucose (quartile 
analysis). There was a significant association with death or major disability (P trend=0.015), 
specifically in the two highest quartiles of admission blood glucose (Q3 aOR 1.31 95%CI 
1.01-1.71; Q4 aOR 1.35 95%CI 1.01-1.80). When admission blood glucose was examined as 
a continuous variable the significant association with poor outcome was also noted (aOR 
1.11, 95%CI 1.00-1.24; P<0.0001). Therefore, our analyses confirm that admission 
hyperglycaemia is an independent predictor of poor outcome, independent of diabetes 
mellitus, haematoma volume, IVH extension and other significant interactions.  
When comparing INTERACT2 results with existing literature, the baseline characteristics of 
other studies must be considered. Specifically, the proportion of patients presenting with 
hyperglycaemia varies across different trials (Table 5.1). This is also affected by differing 
definitions of hyperglycaemia applied in different investigations. I selected 6.5 mmol/L as 
this was the median level of admission blood glucose and allowed effective categorisation of 
patients for quartile analysis. Given that the majority of our patients were from China, the 
proportion of diabetes in the study (11%) was surprisingly lower than other trials. However, 
these 292 patients were enough to provide significant statistical power for outcome analyses. 
The primary outcomes also varied across the ICH trials conducted to date with in-hospital, 
30-day and 3-month mortality and morbidity being investigated. Long-term outcomes (3-
months) were limited by smaller cohort sizes, univariate analysis and conflicting results. My 
analyses of the INTERACT2 cohort overcame limitations of cohort size and multivariate 
analysis showed significant association with poor outcome (death or major disability) at 3-
months.  
Safety outcomes, adverse events and early neurological deterioration in INTERACT2 
analyses 
Analysis of secondary outcomes also provided further information regarding the underlying 
mechanisms in admission hyperglycaemia. Hyperglycaemic patients experienced greater fatal 
adverse events (Table 3.3) primarily caused by the initial haematoma itself. Complications in 
hyperglycaemic ICH patients was earlier explored by Passero et al.
96
 who found greater 
cerebral and infectious complications. My analyses showed that there were significantly 
greater deaths due to the initial ICH (P<0.001) and significantly greater early neurological 
deterioration (P=0.014) in the hyperglycaemic patients. However, there were no significant 
differences in rates of sepsis and respiratory infections between hyperglycaemic and 
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normoglycaemic patients. Early neurological deterioration was measured as decreases in 
GCS (≥ 2 points) or increased ICH severity (≥ 4 points NIHSS score)105. These clinical 
measures of neurological deterioration could be due to evolution of symptoms from the initial 
ICH or attributed to progression of the initial haematoma. As a result, I compared haematoma 
characteristics (haematoma growth and perihaematomal oedema) over the first 24 hours as 
causes of worsening neurological status and as potential mechanisms for the poorer long term 
outcomes in hyperglycaemic patients.  
Safety outcomes were also assessed in the diabetic and non-diabetic patients. In contrast to 
analyses for hyperglycaemia and normoglycaemia, the data on those with diabetes mellitus 
showed significantly greater cardiovascular adverse events (non-fatal) with no associations 
with early neurological deterioration. There were no significant differences in causes of death 
between those with and without diabetes mellitus is in keeping with multivariate model 
finding showing no significant association of diabetes with mortality. Comparing the 
differences in safety outcomes between diabetes and hyperglycaemia reveals that there may 
be distinct mechanisms involved in these two patient groups. The association of diabetes with 
cardiovascular events reflects microvascular and macrovascular complications of the disease. 
To better understand these mechanisms, I explored associations of haematoma growth and 
perihaematomal oedema with admission blood glucose and also history of DM (Chapter 4).  
To elucidate the mechanism underlying adverse outcomes in hyperglycaemia, I examined 
haematoma characteristics based on previous investigations and animal models. Induced 
hyperglycaemia in animal models showed haematoma expansion and exacerbation of 
perihaematomal oedema. However, there has been limited data in clinical trials of ICH 
assessing these parameters. Therefore, in sub-study analysis of the INTERACT2 cohort, I 
explored potential mechanisms explaining the significant neurological deterioration seen in 
the hyperglycaemic group. I hypothesised that hyperglycaemic patients would experience 
greater haematoma growth and perihaematomal oedema 24 hours post-ICH aligning with 
early neurological deterioration reported in hyperglycaemic patients. Surprisingly, there was 
no difference in haematoma growth or perihaematomal oedema in patients with 
hyperglycaemia. These results suggest that hyperglycaemia may play a role in initial 
haematoma growth, with significantly greater baseline haematoma volume but with limited 
change in volume over 24 hours. Haematoma characteristics that were not examined in my 
analyses included hydrocephalus and brainstem compression due to lack of specific data 
collected, which could be explored in future studies.  
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Whilst increased IVH volume is associated with poor outcomes
164
, this was adjusted for in 
multivariate analyses and associations between hyperglycaemia and IVH have been 
previously reported
72
. Appelboom et al.
72
 reported linear relationship between IVH severity 
score and the admission blood glucose level. Further, IVH was found to be an independent 
predictor of critical hyperglycaemia which has been confirmed in the INTERACT2 analyses. 
Hyperglycaemia may exacerbate neuronal injury through blood brain barrier disruption, 
oxidative damage and inflammatory activation thereby causing extension into the ventricular 
system. Therefore, hyperglycaemia is associated with specific severe haematoma 
characteristics and these may contribute to the associated neurological deterioration, 
mortality and major disability. 
Associations of diabetes mellitus and outcome 
Earlier studies have investigated associations between diabetes mellitus and ICH, specifically 
focusing on complications, determinants and outcomes. Arboix et al.
35
 in univariate analyses 
found significantly greater mortality in diabetic patients and in multivariate models reported 
significant association with previous ICH, haematoma affecting multiple locations and 
cranial nerve palsy. INTERACT2 analyses also found that diabetics were significantly more 
like to have experienced previous stroke (ischaemic or undifferentiated), however, found no 
associations with specific ICH location. Baseline differences in diabetic patients reflected the 
shared pathophysiology with cardiovascular disease with significantly greater history of 
hypertension, heart disease and specific medications (beta-blocker, calcium channel blocker, 
anti-hypertensive, insulin therapy) (Table 3S1).  
Interestingly at baseline, diabetic patients had significantly smaller ICH (diabetes 9.2 ml vs. 
non-diabetes 11.2 ml, P=0.002) and combined haematoma volumes (diabetes 11.4 ml vs. 
non-diabetes 13.3 ml, P=0.035) (Table 3S1). There was also no association seen with IVH 
extension or location of haematoma. These baseline characteristics starkly contrast the 
comparison between hyperglycaemic and normoglycaemic patients where hyperglycaemia 
was significantly associated with greater haematoma volumes, IVH extension and specific 
haematoma locations (cerebellar and cortical). These differences between diabetic and 
hyperglycaemic patients indicate distinct mechanisms involved in these patient groups. The 
non-diabetic hyperglycaemic patients are affected by the stress response to the acute 
haematoma with poorer outcomes potentially exacerbated by elevated blood glucose levels. 
In diabetic patients the hyperglycaemia may result from multiple mechanisms including the 
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impaired glucose homeostasis from the disease along with physiological stress response to 
the acute ICH.  
In terms of outcomes, diabetic patients had significantly greater death or major disability 
(aOR 1.43 95%CI 1.03-2.00, P=0.035) and major disability alone (aOR 1.49 95%CI 1.06-
2.10, P=0.023), however, no association with death alone (P=0.743) (see Table 3S3). This 
confirms recent Chinese population study (n=1438) who also reported DM was not a 
significant predictor of mortality.
37
  
Clinical application, Insulin Therapy and Potential for RCT 
My investigation of hyperglycaemia and diabetes mellitus in spontaneous ICH raises the 
question of whether there is a role of targeted insulin therapy for specific blood glucose 
levels. Whilst my data showed no critical threshold of blood glucose, a significant trend was 
observed with increasing levels at admission associated with poorer outcomes. Current 
guidelines are far from comprehensive regarding the approach to hyperglycaemia in ICH.  
Older studies investigating the role of intensive insulin therapy in Intensive Care Units 
provided positive evidence for this approach. A ‘landmark’ trial by van den Berghe et al.165 is 
frequently cited. This prospective, randomised controlled trial (n=1548) compared 
conventional (target blood glucose: 10.0-11.1 mmol/L) to intensive therapy (target blood 
glucose: 4.4-6.1 mmol/L). 4% of these patients were admitted in ICU for neurologic disease 
with the majority being post-cardiac surgery. Benefits reported from this trial included 
reduced ICU admission length, decreased rates of septicaemia, less prolonged requirement 
for ventilation and most importantly reduced mortality. These findings were supported in a 
later Chinese study
166
.  
However, subsequent trials have yielded mixed results in terms of the benefits of intensive 
insulin therapy (IIT) in critically ill patients. Meta-analysis of these patients (n = 8432) 
showed no significant difference with in-hospital mortality.
167
  Adverse event analysis 
showed significantly greater hypoglycaemic events but also showed significantly lower 
incidence of septicaemia in the IIT group. It should be noted that inclusion criteria was for 
ICU patients and represented a wide range of patient types (cardiac surgery, acute 
cerebrovascular events, trauma, acute coronary syndrome, sepsis). Further systematic 
reviews
168-170
 found no survival benefit and significantly greater IIT-induced hypoglycaemic 
events. Arabi et al. investigated the clinical significance of this hypoglycaemia and reported 
no significant difference in mortality when compared with controls.
171
 In patients with critical 
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hypoglycaemia (BSL < 1.2 mmol/L) a trend towards poorer outcomes was noted but this was 
not statistically significant in multivariate analyses.  
Whilst aforementioned studies focused on medical and surgical ICU patients, more recent 
trials have been conducted in stroke with the majority of literature examining on acute 
ischaemic stroke. An early pilot study tested the safety and tolerability in controlling BSL 
between 5-8 mmol/L and found that insulin requirements decreased within 48-hours 
suggesting a role for early aggressive therapy to control glycemic control.
172
 The randomised 
pilot study (THIS)
173
 explored the differences in clinical outcomes at 3 months by looking at 
mRS scores ≤2, Stroke-Specific Quality of Life, modified Barthel Index and NIHSS. 
Hypoglycaemic events were experienced in the IIT group, however, these were mostly 
asymptomatic and easily resolved. Whilst clinical outcomes were more favourable in the IIT 
patients these results were not statistically significant. This study has been extended upon 
with the SHINE trial which is currently underway.
174
 This investigation will compare 
standard vs. intensive insulin management in hyperglycaemic stroke patients with targeted 
cohort of 1400 patients. The primary end-point will be 90-day clinical outcome using 
modified Rankin scale.  
The INSULININFARCT trial examined the effect of IIT upon infarct growth using MRI 
imaging. Although more optimum glycaemic control was achieved with IIT, this therapy was 
also significantly associated with larger infarct growth. However at 90-days there was no 
difference in mortality or serious adverse events.
175
 Further analysis of a sub-group of this 
trial (n=99) examined the effect of insulin therapy upon the penumbral region. 
Hyperglycaemic patients experienced worsened ischaemic damage; however, the insulin 
therapy had no effect upon severity of ischemia.  
In ICH there is limited literature regarding the role of IIT. Godoy et al.
176
 studied the effect of 
insulin therapy. Whilst mild hypoglycaemia was reported it was associated with no 
significant adverse outcomes. There was no change in mortality in patients treated with 
insulin for tight glycemic control.  
At this stage there is not enough evidence regarding the potential of IIT in ICH. From 
INTERACT2 analyses, where significant associations were observed with hyperglycaemic 
patients and early neurological deterioration and later clinical outcomes (3-months), there is a 
definite need for further investigation into the effect of tight glycaemic control upon outcome. 
Although our sub-study analysis showed no association with haematoma growth and 
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perihaematomal oedema, further confirmatory investigation is required and other haematoma 
characteristics such as hydrocephalus and brainstem herniation must be examined. The 
majority of patients in INTERACT2 were of mild-moderate severity (based on NIHSS score). 
Assessing the role of hyperglycaemia in different severity ICH would also be useful.  
I recommend the undertaking of a randomised pilot trial to examine the safety and tolerability 
of IIT in ICH, before proceeding to a large scale clinical endpoint trial. Specifically, I would 
examine in-hospital mortality, hypoglycaemic events, infectious and cerebral complications 
during hospital admission. Three-month clinical outcomes would also be assessed (death or 
major disability). We would also want to determine differences in haematoma growth, 
perihaematomal oedema following tighter glycaemic control. With the difference in 
hyperglycaemia based on location reported, it may also be interesting to investigate if deep 
vs. cortical haematomas are more responsive to aggressive insulin therapy.  
However, before proceeding to a large-scale clinical trial it is essential to directly examine 
the relationship between glycaemic control and intracerebral haematoma growth. A proof-of-
concept (PoC) trial would allow the signal between tight glycaemic control and haematoma 
growth to be assessed and may also provide preliminary insights into the efficacy of this 
therapy. Specifically, it would assist in examining the association between tight glycaemic 
control and increases in haematoma volume, intraventricular extension and perihaematomal 
oedema.  
The advantages of PoC studies are in their simplified study design and small-scale approach 
which limits funding requirements and overcome issues of timing related with large clinical 
trials. Examining adverse events such as rates of hypoglycaemia will also provide integral 
information regarding the safety of tighter glycaemic control in intracerebral haemorrhage 
patients. These studies may also suggest an optimum therapeutic window for glycaemic 
control. Results from such trials will assist in determining the need and benefit for further 
larger-scale investigation.  
Limitations of PoC trials must also be considered. Statistical power will be reduced by 
smaller sample sizes and potential confounding variables such as age, gender, medical history 
(hypertension, coronary artery disease), medications (anti-coagulation, anti-platelet therapy, 
anti-hypertensives) must be considered and adjusted for. The time required for recruitment of 
suitable patients is another factor that could reduce efficiency of the trial.  
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A number of recent trials have investigated outcomes associated with intensive insulin 
therapy in neurocritical care and acute ischaemic stroke with varying results. Poorer 
outcomes with significantly higher hypoglycaemic events and higher mortality have been 
reported
177
  with 71% incidence  of hypoglycaemia found in ischaemic stroke patients.
178
 The 
INSULINFARCT trial
179
 also studied insulin therapy in ischaemic stroke and whilst 
hyperglycaemia exacerbated neuronal ischaemia, there was no improvement in infarct 
volumes in patients receiving intensive insulin therapy.  Therefore the ethical considerations 
of performing PoC studies must be taken into account as aggressive insulin therapy may 
subject patients to potentially significant harm. Before commencement these risks must be 
examined, however, a PoC trial with small sample size may provide a vital starting point in 
understanding the role of insulin therapy in intracerebral haemorrhage.  
Overall, my investigation has provided a comprehensive overview on the role of 
hyperglycaemia in ICH with the recommendation for a proof-of-concept study comparing 
intensive and standard glycaemic control in ICH.  
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Table 5.1: Overview of studies assessing association hyperglycaemia and outcomes at 1-month and 3-month 
Study  
Cohort 
Size 
% 
Hyperglycaemia 
% Diabetes 
Hyperglycaemia 
definition 
Outcome 
Critical 
Level 
AOR P value 
Early 
Outcome 
                
Appelboom 104   23.20% 10mM Discharge Mortality 10mM 4.381(1.186–16.174) 0.03 
Franke 157 50.30% N/A ≥8 mmol/L 2-Day Mortality >8mM 5.5 0.01 
Samiullah 399 27.30% 
  
≥7 mmol/L (fasting) 
or ≥8.6 mmol/L 
In-Hospital 
Mortality   
10.9(4.72-25.32) <0.001 
Tetri 379 33.80% 17.94% >8.0mM 2 day Mortality - 1.04 (0.95–1.13) Not Significant 
Kimura 100   Not Reported >150 mg/dl 14-Day Mortality >150 mg/dl 37.34(1.40-992.73) 0.031 
Outcome at 
1-month               
 
  
Fogelholm 290   11.90% 9.1 mM 28 day Mortality   1.22(1.07-1.40) 0.004 
Bejot  465     ≥8.6 mmol/L 1-Month Mortality ≥8.6 mmol/L 2.51(1.23-2.43) 0.002 
Lee 1387   11.60% - <30 day Mortality - 1.10(1.01-1.19) 0.03 
Lee  1119   NDM - Non-DM, <30 day - 1.11(0.999-1.22) 0.053 
Passero 637 43.20% 17% ≥130 mg/dl 30 day Mortality ≥130 mg/dl 1.099(0.947-1.275)**   
Godoy 295 
  
50.17% 
≥7.22 mmol/l or 130 
mg/dl 
30-Day Mortality 9.08 mmol/l 1.51(1.23–1.85) <0.0001 
Tapia-Perez 116   31.90% >140 mg/dL 30-Day Mortality >140 mg/dL 2.65(1.15–6.12) 0.02 
Tan  3756 39.60% N/A ≥7.5mM 
In-hospital to 1-
month Mortality 
- 3.46(1.66-7.20) 0.0009 
Outcome at 
3-months             
 
  
Passero 637 43.20%   ≥130 mg/dl 3-Month Mortality ≥130 mg/dl 1.086(0.941-1.253)**   
Appelboom 104     10mM 3-month Mortality 10mM 10.85(1.886–62.41) 0.02 
Tetri 379     >8.0mM 3 Month Mortality - 1.04 (0.99–1.10) Not Significant 
INTERACT2 2653 61% 11% >6.5mM 
3-Month Death or 
Major Disability 
- 1.11 (1.00-1.24) P<0.0001 
INTERACT2 2653 61% 11% >6.5mM 3-Month Mortality - 1.16 (1.01-1.33) P=0.043 
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Table 5.2: Other studies investigating associations between hyperglycaemia and poor outcomes in ICH 
Study  
Cohort Size 
% 
Hyperglycaemia 
% Diabetes 
Hyperglycaemia 
definition 
Outcome 
Critical 
Level 
AOR 
P 
value 
Sun 149 
  
23.50% ≥140 mg/dl 
Late Neurological 
Deterioration 
140 mg/dl 
2.614 (1.146–
5.965) 
0.022 
Zhang 54 - DM group - Poor Outcome, mRs >2 - 
1.109(0.704–
1.394) 
0.078 
Zhang  
234 - NDM group - Poor Outcome, mRs >2 - 
0.995(0.763–
1.26) 
0.105 
Qureshi 60 42% N/A - modified Rankin Score 4-6 114 mg/dl 
2.64(1.03-
6.75)   
Stead 237 19.80%   140 mg/dl       0.0037 
Feng 135 33.30% 19.26% ≥150 mg/dl modified Rankin Score ≥3 ≥150 mg/dl     
Lee 1387 
  
11.60% - > 30 day Mortality - 
1.05(0.98-
1.11) 
0.15 
Lee 1119 
  
NDM - Post-ICH Mortality - 
1.10(1.03-
1.17)   
Lee 
    
NDM - Non-DM, >30 day - 
1.07(0.99-
1.16) 
0.09 
Wu 62 N/A 27.40% ≥140 mg/dl 
Poor Outcome, Glasgow 
Outcome Scale 
≥140 mg/dl 25.217 0.008 
Bejot 465 
    
≥8.6 mmol/L Function Handicap 
≥8.6 
mmol/L 
2.51(1.43-
4.40) 
0.01 
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